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Abstract 
Green tea has been consumed for thousands of years and its concentrated extract is 
now a popular herbal supplement frequently consumed in isolation or as part of a 
multi-ingredient product. Green tea extract (GTE) is commonly used for its wide 
range of purported health benefits and, as with most herbal supplements, its sale on 
the Australian market is regulated by the Therapeutic Goods Administration without 
requiring pre-market safety or efficacy analysis. Unfortunately, GTE has been 
implicated in over 50 cases of liver damage in the last 20 years, a number of which 
resulted in transplantation as the only option for patient survival. Despite the clear 
link between this supplement and liver injury in these individuals, little is currently 
known in regards to which biochemical pathways are affected during GTE-induced 
hepatotoxicity and the extent to which this is mediated by metabolic products of 
GTE. 
In this study, GTE and individual catechins were metabolised with S9 human liver 
fraction and subsequently analysed using untargeted metabolomics. The results 
confirmed that some metabolism of the GTE had occurred, with the production of at 
least 17 GTE metabolites. Of these suspected metabolites, 10 were also found in the 
metabolised catechins, suggesting that more than half of these compounds were 
metabolites of the catechins in GTE. 
To assess hepatotoxicity, HepG2 cells were exposed to either unmetabolised or 
metabolised GTE at doses equivalent to 1 mg/mL. Additionally, to assess the impact 
of GTE on drug-induced liver injury, another group of cells were exposed to 15 mM 
paracetamol, 1 mg/mL GTE or a combination of both treatments.  The exposure 
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period for all treatments was 24 h, after which small molecule metabolites were 
extracted from harvested cells and analysed using untargeted metabolomics. 
Changes were observed in amino acids, carbohydrates and fatty acids in all treatment 
groups, and the same biochemical pathways appeared to be affected in all GTE 
treatment variations. Cell treatment with GTE metabolites appeared to yield less 
cytotoxicity than those treated with unmetabolised GTE. It was unable to be 
determined whether GTE exacerbated paracetamol-induced hepatotoxicity from the 
results obtained in this study.  
Overall, the findings from this study suggested that GTE causes disruption to cellular 
lipids, proteins, nucleic acids and the mitochondria, potentially as a result of 
oxidative stress. Given the popularity and ready availability of GTE, regulation of 
herbal supplements containing this product must be improved to ensure consumer 
safety and ultimately prevent further cases of liver damage.  
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1. Introduction 
Herbal complementary and alternative medicines (HCAMs) are becoming an 
increasingly popular therapeutic choice amongst consumers, largely due to the 
perception that their natural origin indicates they are a safer option compared to 
conventional medicines.1 Green tea extract is a herbal medicine that has a wide range 
of purported benefits, such as its ability to aid in weight loss and the prevention and 
management of certain chronic diseases, believed to be due to its high catechin 
content.2 
Over the last 20 years there have been more than 50 cases of liver injury in which 
green tea extract has been implicated, with the most severe cases requiring liver 
transplantation.3, 4 The idiosyncratic, acute onset has made it difficult to predict 
which individuals may be predisposed to a hepatotoxic response to this HCAM.3, 4 It 
is currently unknown which green tea extract constituents or metabolites are 
responsible for this liver damage, although the catechins are suspected due to their 
presence in high concentrations. Additionally, the mechanisms by which the 
hepatotoxicity occurs are also poorly understood. 
Using metabolomics for hepatotoxicity analysis is a novel approach which may 
provide insight into both of these unknowns by providing a snapshot of the 
metabolome following exposure to green tea extract and its metabolites, enabling 
conclusions to be drawn about the biochemical responses to these compounds.5 
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1.1 Herbal complementary and alternative medicines 
1.1.1 Background 
Complementary and alternative medicines (CAMs) have become an increasingly 
popular therapeutic option around the world in recent years, with an estimated two-
thirds of the Australian population using these medicinal products.1, 6, 7 This 
popularity led CAM revenue in Australia to reach $4.9 billion in 2018.1, 8 
HCAMs make up a large portion of CAM sales and are typically taken in a bid to 
maintain or enhance the consumer’s health.8 They contain ingredients derived from 
plants, parts of plants (e.g. leaves, flowers, seeds and roots) or other organisms which 
the International Code of Botanical Nomenclature regards as plants (e.g. yeast, fungi 
and algae).9 HCAMs are typically complex multicomponent substances, however, due 
to their natural origins they are generally perceived by consumers to be safer than 
conventional medicines.1, 10 This, however, is a misconception as HCAMs, like 
pharmaceuticals, contain active ingredients capable of causing adverse effects in the 
consumer.6 For this reason, they are required to be evaluated by the Therapeutic 
Goods Administration (TGA) prior to going on the Australian market.9 
1.1.2 Regulation of HCAMs 
The TGA requires that all medicinal products, including HCAMs, be either registered 
or listed with the Australian Register of Therapeutic Goods (ARTG) in order to be 
marketed.9 Whether a medicine is registered or listed is based on whether the 
product’s ingredients are deemed high- or low-risk, respectively, along with its 
indication.9  For a medicine to be registered, the TGA assesses the product to ensure 
its safety, efficacy and quality before approving its addition to the ARTG.9 The 
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evaluation of a medicinal product is carried out based on an extensive report 
provided to the TGA by the manufacturer, which should include data to support the 
efficacy, safety and quality of the substance.9 
Medicines may instead be listed if they are composed of low-risk ingredients at 
appropriate concentrations, manufactured in compliance with Good Manufacturing 
Practice and are only indicated for certain “non-serious, self-limiting conditions” or 
health maintenance and enhancement.9 The TGA does not assess the indications on 
medicines applying for listing on the ARTG.9 Instead, manufacturers must only claim 
to have recorded evidence for their product’s efficacy.9 Whilst they must make this 
information available to the TGA should they request it, it is not a requirement to 
prove they have the documentation in order to be listed.9 
The TGA carries out annual compliance reviews on listed medicines; however, due to 
the sheer number of listed products it is impossible to evaluate all of them.9 Instead, 
random or targeted reviews for noncompliance are undertaken, based on a risk 
management approach employed to identify priority substances.9 Random 
compliance reviews are carried out on a proportion of newly listed medicinal 
products, chosen using a computer-based mathematical model.9 Targeted 
compliance reviews are also carried out on listed products which have been 
highlighted as being potentially noncompliant.9 
The vast majority of HCAMs are listed on the ARTG, meaning they face less stringent 
regulation than mainstream medicines.11 This enables them to reach the Australian 
market with relative ease.6, 9 This in turn is associated with a greater risk to the 
consumer, and leaves many questions surrounding the efficacy, quality and safety of 
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HCAMs.6, 7, 12, 13 To date, a number of safety concerns in relation to HCAM usage have 
been identified, including from research carried out at Murdoch University.7, 12 
1.1.3 Safety issues with HCAMs 
The consumption of HCAMs is associated with a number of safety issues which pose 
a considerable risk to the consumer; for example, batch and product variation, 
contamination, adulteration and the ability of consumers to self-prescribe without 
medical supervision.12-17 
The chemical composition of a given HCAM is subject to variability.7, 14, 15 This 
variation may be due to differences between plant species and variety, growth 
conditions, time and season of harvest, the geographical origin of the herbal 
materials and the harvesting and handling processes involved.7, 15 These factors alone 
can result in significant variation among batches of the same herbal medicine, and 
also between different products containing the same ingredients.7, 14 
A number of HCAMs have been found to be contaminated or adulterated.7, 12, 13 An 
example of a chemical contaminant found in HCAMs is heavy metals.12  A 2015 study 
found arsenic levels well over 10 times the recommended daily limit in one particular 
traditional Chinese medicine.12 This is of particular concern given that arsenic is a 
highly toxic metal which has the potential to cause serious adverse reactions in the 
consumer, or even death.12 Perhaps more concerning is the fact that some HCAMs 
have been found to have been intentionally adulterated, with parts of exotic animals 
and pharmaceutical medications, such as anti-inflammatory drugs.12, 13 A 2018 paper 
found that a number of St John’s Wort samples contained food dye, which was 
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suggested to be a method used by some manufacturers to pass spectroscopic 
analysis with a product that is of inadequate quality.13 
Additionally, the ability of the consumer to self-prescribe poses another risk, 
particularly as many individuals do not disclose their herbal remedy regime to their 
medical practitioners.16, 17 This opens up the potential for herb-herb interactions, if 
the individual is taking multiple herbal remedies, and drug-herb interactions, if they 
are prescribed a pharmaceutical by a doctor who is unaware of the other substances 
being consumed by their patient.16, 17 
HCAMs, like other xenobiotics, are metabolised in the liver.18, 19 For this reason, the 
liver is the main target of toxicity should an ingested substance contain toxic 
compounds, heavy metals or undisclosed pharmaceuticals.18, 20, 21 Additionally, 
herbal compounds may be metabolised into toxic products during hepatic 
metabolism, increasing the risk of hepatotoxicity.18 Thus, HCAMs are becoming 
increasingly implicated in cases of liver damage.22 
1.2 Hepatotoxicity 
1.2.1 Xenobiotic metabolism in the liver 
The liver is the major site of xenobiotic metabolism, where molecules are converted 
into a more hydrophilic form with decreased biological activity in order to enable 
excretion via the kidneys.18, 19 There are two main phases involved in the 
biotransformation process and, depending on the type, xenobiotics may go through 
one or both of these phases prior to being eliminated from the body.18, 19 
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Phase I involves the modification of a molecule via oxidation, reduction and 
hydrolytic reactions to make the xenobiotic more polar, enhancing its water 
solubility.19 This changes the biological activity of the xenobiotic and can be a crucial 
step in the activation of prodrugs.18 The most important enzymes in Phase I 
metabolism are those of the cytochrome P450 (CYP450) superfamily.19 It is 
predominantly the CYP 1-4 families that are involved in xenobiotic metabolism and, 
of these, CYP3A4 is the most abundant.18, 19 
In Phase II, xenobiotics or their metabolites from Phase I are conjugated with 
endogenous compounds via the action of transferase enzymes.18 This process 
generally renders biologically active metabolites inactive and the resulting metabolic 
products are more readily excreted.18 Examples of reactions involved in Phase II 
metabolism are glucuronidation, sulfation and glutathione conjugation.18, 19 The 
majority of these reactions occur in the cytosol, excluding glucuronidation, which is 
carried out in microsomes and mediated by the uridine diphosphate-
glucuronosyltransferase (UGT) enzymes.18 
A third phase was first suggested in 1992, accounting for the efflux of metabolic 
products produced during the biotransformation phases.23 Phase III is considered a 
detoxification reaction, as it is responsible for the final transport of drug molecules 
out of the liver for excretion.23 Whilst no metabolic processes occur during this 
phase, it is important to consider as it has been found that polymorphisms in these 
transporters or inhibition of their activity may predispose certain individuals to herb 
or drug-induced liver injury.24, 25 
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Whilst hepatic metabolism plays an important role in preparing xenobiotics for 
elimination, it can also be responsible for the production of toxic metabolites.18 The 
accumulation of toxic compounds in the liver or metabolic activation of such 
substances may cause hepatotoxicity.18, 24 For example, whilst the majority of 
paracetamol (APAP) is metabolised via Phase II metabolism, approximately 5-15% is 
oxidised by CYP450 enzymes into the highly reactive metabolite N-acetyl-p-
benzoquinone imine (NAPQI).26 At therapeutic doses, glutathione-mediated 
detoxification prevents the accumulation of this toxic metabolite.26 In the event of 
an overdose glutathione becomes depleted, leading to NAPQI build-up and 
ultimately hepatotoxicity.26 
1.2.2 Herb-induced liver injury 
Drug-induced liver injury (DILI) is a major cause of acute liver failure worldwide.27 The 
proportion of these cases that result from herbal medicines has been difficult to 
determine, given the widespread use of HCAMs and underreporting of this usage to 
healthcare professionals.1, 16 However, a recent review found that herbs were 
implicated in approximately 25% of all DILI cases.22 
The majority of herb-induced liver injury (HILI) cases are idiosyncratic, in which the 
cause of damage is dose-independent and unpredictable.22 The pattern of injury 
observed in HILI cases is predominantly hepatocellular, which is associated with 
cellular necrosis and inflammation.4, 22, 28 Cholestatic and a mixed type of injury have 
also been observed to a lesser extent.4, 22, 28 Cholestatic injury occurs when bile flow 
from the liver reduces or ceases due to damage to the bile ducts, resulting in its 
 8 
accumulation in the hepatocytes, while the mixed pattern of injury includes both 
hepatocellular and cholestatic characteristics.2 
Due to the unpredictable nature of HILI, the mechanisms of hepatotoxicity are better 
understood for DILI.29 There are a number of processes involved in DILI that have 
been identified, and it is often a combination of these that contributes to the 
development of liver damage.29, 30 Death of hepatocytes via apoptosis or necrosis can 
occur as a result of exposure to toxic metabolites formed during the 
biotransformation of medicinal compounds.18, 29 Reactive metabolites can act on a 
range of cellular molecules, resulting in loss or change in protein function, lipid 
peroxidation or damage to DNA.29 These metabolites may also induce an immune 
response or stress in the mitochondria and endoplasmic reticulum.29, 30 The 
activation of immune cells results in inflammation, which may exacerbate tissue 
damage in the liver.29 
Herbs contain multiple compounds and even single-ingredient HCAMs are chemically 
complex.10 This is worsened by individuals taking additional herbal or conventional 
medicines, increasing the risk of herb-herb or herb-drug interactions, which could 
also trigger liver injury.16, 17 Whilst HILI cases have been observed in individuals taking 
a single-component herbal medicine, those taking multicomponent HCAMs or 
concurrently taking multiple herbs or medicines have been found to be at an 
increased risk of liver damage.4 Liver injury in these individuals tends to be more 
severe than that observed in individuals taking a single herbal medicine, and females 
have been found to be more susceptible to HILI than males.4, 22, 28, 31  
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It has been suggested that factors such as administration conditions and 
polymorphisms in certain genes may influence an individual’s predisposition to 
developing HILI or DILI.32-34 Fasting may affect the bioavailability or systemic 
clearance of some biologically active compounds, thus individuals who take HCAMs 
in a fasted state may be at an increased risk.32, 33 Significant genetic variation occurs 
in important biological molecules such as the CYP450 enzymes and major 
histocompatibility complex (MHC) classes I and II.34, 35 Polymorphisms such as these 
may predispose certain individuals to a heightened susceptibility to hepatotoxicity, 
although a clear link is yet to be established.34, 36 Specific polymorphisms suspected 
to influence the susceptibility of an individual to DILI or HILI have been found to occur 
at higher frequencies in certain ethnic groups.34 For example, a CYP2B6 
polymorphism is associated with increased susceptibility to ticlopidine DILI and 
occurs more frequently in Asian populations than European.34, 36 It is theorised that 
polymorphisms such as this may partly explain why DILI/HILI is more prevalent in 
individuals of certain ethnicities.35 
There are additional risk factors associated with DILI which may also influence the 
likelihood of HILI.37 It is unclear whether elderly individuals have an increased 
susceptibility to DILI, however it has been observed that the pattern of injury tends 
to be cholestatic as opposed to the predominance of hepatocellular injury in those 
who are younger.37 The reason for this is not yet fully understood, however it may 
be phenotypic or dependent on the type of drug consumed.37 Additionally, whilst 
there is currently no data suggesting that individuals with an underlying liver 
condition are at a higher risk for developing DILI, there appears to be an increased 
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likelihood that they will suffer more severe reactions when liver damage does 
occur.37 
Dosage must also be taken into consideration as it has been suggested that, in the 
belief that HCAMs are harmless, some individuals may take more than the 
recommended daily dose in order to achieve their desired results sooner.4 For 
example, some athletes may turn to supplements rich in antioxidants in order to 
combat the oxidative stress induced by exercise.38, 39 Those that choose to take 
additional supplements may end up with liver damage, as studies have shown that 
an excessive intake of antioxidants may have a pro-oxidative effect.40, 41 
Alarmingly, certain HCAMs that are marketed as being hepatoprotective have been 
implicated in cases of HILI.42, 43 One such herbal medicine which has been gaining 
attention for its implication in hepatotoxicity is green tea extract (GTE).4, 43-45 In 
addition to potentially causing hepatotoxicity in its own right, it has been found that 
GTE may exacerbate liver injury caused by other drugs or herbs.46 For example, 
numerous studies have demonstrated that GTE exacerbates paracetamol-induced 
liver injury, even when consumed at therapeutic doses.46-48 
1.3 Green tea extract 
1.3.1 Composition 
Green tea has been consumed for thousands of years and has a reputation for having 
numerous health-promoting properties, resulting in its popularity continuing to 
increase.49 GTE is a concentrated form of the tea derived from the leaves of the 
Camellia sinensis (L.) plant.2 Unlike other teas, green tea is not fermented prior to 
drying and thus the high concentration of polyphenols found in the leaves is 
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retained.50 For example, it has been found that green tea has a polyphenol content 
up to 100 times higher than black tea.50 In addition to the polyphenols, GTE also 
contains methylxanthine alkaloids and phenolic acids, such as gallic acid.51 Other 
constituents commonly found in dried green tea leaves include proteins; amino 
acids, approximately 50% of which is theanine, an N-methylated derivative of 
glutamine; carbohydrates, such as glucose; vitamins, such as vitamin C; minerals and 
trace elements, such as potassium and aluminium; pigments, such as chlorophyll; 
and volatile compounds, such as aldehydes.50, 51 
Of its many constituents, the major pharmacologically active compounds of green 
tea are the polyphenols and methylxanthine alkaloids.51 The main methylxanthine 
alkaloid found in green tea is caffeine, although some GTE supplements may be 
decaffeinated.51, 52 Other examples of these compounds include theophylline and 
theobromine, although the quantities present in tea leaves are believed to be 
minimal, with levels as low as 0.02 and 0.1% reported in the literature, respectively.51 
Whilst the methylxanthine alkaloids, particularly caffeine, are biologically active, it is 
the polyphenols that are believed to be responsible for the broad range of health 
benefits claimed to be associated with GTE consumption.51, 53 
1.3.1.1 Catechins 
The most important polyphenols are the catechins, which are secondary plant 
metabolites that readily scavenge free radicals, an important property responsible 
for the antioxidant role of green tea.51 The main catechins found in green tea are (-)-
epigallocatechin-3-gallate (EGCG), (-)-epigallocatechin (EGC), (-)-epicatechin gallate 
(ECG), (-)-epicatechin (EC), with (-)-catechin and other isomers present to a lesser 
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extent (Figure 1).50, 54 The general consensus appears to be that EGCG is the most 
abundant green tea catechin (GTC) and primarily responsible for the various health-
promoting properties associated with its consumption.55 Some studies have found 
other catechins to be present in a higher concentration than EGCG, however this may 
be due to catechin concentration being highly dependent upon the age of the leaf 
from which the tea is derived, with first leaves and buds having been found to contain 
the highest EGCG concentrations.50, 51 In addition to the catechins, there are other 
polyphenols found in green tea, such as quercetin, however these are present in 
significantly lower concentrations.51, 55 
The catechins share a chemical structure composed of one dihydropyran heterocyclic 
ring and two benzene rings, but differ based on the presence or absence of additional 
functional groups (Figure 1).51 The gallocatechins, such as EGC, have an additional 
hydroxyl group on the B-ring; the catechin gallates, such as ECG, have a gallic acid 
group esterified to the hydroxyl group on the pyran ring (Figure 1.1).51 
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Figure 1.1 Chemical structure of the four main catechins found in green tea.56 The catechins each 
contain two benzene rings (A, B) and one dihydropyran heterocyclic ring (C).51 EGC and EGCG are 
classified as gallocatechins due to the addition of a third hydroxyl group on the B-ring.51 EGCG is also 
classified as a catechin gallate, along with ECG, due to the esterification of a gallic acid group (D) to 
the hydroxyl group on the dihydropyran ring.51 
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1.3.2 Catechin metabolism 
As with other GTE components, GTCs undergo biotransformation in the liver prior to 
being excreted.57-59 Phase I metabolism of GTCs has not yet been observed in in vitro 
or in vivo studies, however, it does appear that they may inhibit the activity of certain 
CYP450 enzymes.60, 61 For example, GTE and EGCG have been found to 
noncompetitively inhibit CYP3A4 and competitively inhibit CYP2B6 and CYP2C8.60 
This inhibition of CYP450 enzymes appears to be clinically relevant, and may impact 
the Phase I metabolism of other drugs co-administered with GTE supplementation.60 
Catechins are predominantly metabolised via Phase II processes, with 
glucuronidation, sulphation and methylation appearing to be the major reactions 
involved in the biotransformation of these compounds.54, 57-59 The extensive Phase II 
metabolism of GTCs yields a wide range of metabolites; this is demonstrated by the 
full metabolic profile of EGCG, comprising 22 metabolites, shown in Figure 1.2.61 
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Figure 1.2. Overview of the pathways involved in EGCG metabolism.61 Catechins are metabolised via 
Phase II reactions such as glucuronidation, sulfation and methylation.61 These compounds may 
undergo several Phase II reactions, leading to the production of a large variety of catechin 
metabolites.61 The metabolic profile of EGCG depicted here demonstrates that at least 22 different 
metabolites can be produced from this catechin alone.61 
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It is  important to note that GTCs may be metabolised at other sites in the body, 
including the small intestine or via microbial metabolism in the colon.59, 62 For 
example, a 2000 study that used rats to understand the metabolism of catechin and 
EC in the small intestine found that, depending on the location of absorption, GTCs 
may undergo methylation, glucuronidation and/or O-methyl-glucuronidation via 
various enzymes during their transfer through enterocytes.62 This has been found to 
occur with catechins absorbed in the jejunum, resulting in a significant proportion of 
these compounds entering the portal vein already partially metabolised.62 In 
contrast, this does not appear to occur with catechins absorbed in the ileum, with 
these compounds being transferred to the portal vein unmetabolised.62 Additionally, 
it was found that the total percentage of catechins that reach the portal vein via the 
ileum was approximately 5-fold greater than those absorbed in the jejunum.62 
1.3.2.1 Methylation 
GTCs undergo methylation by cytosolic catechol-O-methyl-transferase (COMT), with 
all four of the main catechins having been demonstrated to undergo this process.57 
In COMT-mediated methylation, a methyl group from S-adenosylmethionine is 
transferred to the compound being metabolised.19 Compared with EGC and EC, lower 
O-methylation rates have been demonstrated with EGCG and ECG; however, it has 
been found that glucuronidation on the B- or D-ring of EGCG inhibits methylation of 
the same ring, which may explain this observation (Figure 1).57 At high concentrations 
of EGCG, monomethylated EGCG metabolites are the most prevalent, whilst at low 
concentrations the majority of EGCG metabolic products are dimethylated.57 In 
addition to being methylated by COMT, EGCG has also been observed to 
 17 
noncompetitively inhibit its activities by binding to a different site instead of the 
catechol binding site.57 
1.3.2.2 Glucuronidation 
Glucuronidation involves the production of uridine 5’-diphosphoglucuronic acid 
(UDPGA) in the cytoplasm, which is subsequently transported into the endoplasmic 
reticulum where UGT can catalyse its conjugation to the compound being 
metabolised.19 EGCG and EGC have been demonstrated to undergo glucuronidation 
in the liver, with UGT1A1, UGT1A8 and UGT1A9 being the main enzymes responsible 
for these reactions, although UGT1A8 has been shown to have low activity with 
EGC.58 A 2003 study found that the major EGCG glucuronide formed is EGCG-4’’-O-
glucuronide.58 
1.3.2.3 Sulfation 
Sulfotransferases (SULTs) are Phase II enzymes which are responsible for the 
sulfation of compounds, a process which is essential for the metabolism of many 
exogenous substances.19 There are two forms of SULT, one found in the cytosol and 
one which is membrane-bound; it is the cytosolic SULTs which are metabolically 
important.19 These enzymes conjugate 3’-phosphoadenosine 5’-phosphosulphate 
(PAPS) to sulfur, nitrogen or oxygen atoms in the compound being metabolised.19 
Sulfation of EC has been found to occur primarily through the action of SULT1A1, the 
SULT responsible for metabolising phenols, amines and alcohols.19, 56, 59 Sulfation of 
EGCG has also been demonstrated, although in this case it appears to be 
concentration- and time-dependent.56, 59 
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1.3.3 Uses of GTE 
GTE is widely used for its abundant antioxidants and claimed health benefits, 
including weight management, anti-inflammatory properties and protection against 
a number of chronic diseases.2, 63 For example, GTE is supposedly able to protect 
against, or alleviate the symptoms of, cardiovascular and liver diseases, Diabetes 
mellitus, Alzheimer’s disease and even cancer.43, 55, 64-66 These benefits of green tea 
have been extensively researched, with many studies yielding promising results, 
however it is worth noting that there have also been conflicting reports in the 
literature.67, 68 For this reason, further research is required in order to confidently 
establish whether GTE is capable of preventing or treating these diseases in a 
clinically significant manner. 
One of the most popular applications of GTE is for its purported ability to stimulate 
weight loss, a claim which has been researched extensively using mouse models and 
human studies.2, 69-72 The literature is inconclusive as to whether GTE 
supplementation leads to weight loss, although it seems that it may yield a modest 
reduction in weight, but only when administered at high doses.72 It appears that a 
catechin-caffeine combination is required for this weight loss to occur, with studies 
using decaffeinated GTE yielding no significant reduction in weight.52, 73 Furthermore, 
this weight loss is often clinically insignificant, therefore supplementation with GTE 
for this purpose is unlikely to yield substantial results in the consumer.74 
Whilst most individuals appear to be able to consume GTE regularly without ill effect, 
there are a number of cases of hepatotoxicity that have been associated with this 
supplement.4 The majority of these GTE-induced liver damage cases appear to occur 
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in individuals taking the supplement for weight loss purposes.4 As outlined above, 
the dosage required to achieve significant weight loss is likely to be higher than the 
recommended daily limit and, in the belief that the supplements are harmless due to 
their natural origin, consumers may be inclined to take extra doses to obtain the 
results they are looking for. 74 In addition to this, it is currently unknown whether 
long-term consumption of GTE is safe, thus individuals using it for extended periods 
of time, regardless of the purpose, could also be at an increased risk.2 
1.3.4 Hepatotoxicity of GTE 
In June 2018, the TGA issued a safety advisory for consumers and healthcare 
professionals to alert them to the potential for GTE-induced liver damage.44 At that 
time, 20 cases of hepatotoxicity associated with GTE consumption had been reported 
to the TGA, and three of these cases involved products containing only C. sinensis as 
the active ingredient.44 Hepatotoxicity associated with GTE is generally seen in 
individuals using the supplement for weight loss purposes.45, 75-81 The predominant 
pattern of liver injury is hepatocellular, with the acute onset of liver damage at times 
so severe that liver transplantation is the only treatment option.45, 75, 79, 81-85 In cases 
where the hepatotoxicity is caught early, the liver injury was resolved simply by 
discontinuing consumption of GTE.75, 76, 83, 85 In instances where these patients have 
rechallenged their system with GTE, recurrence of hepatotoxicity has been 
observed.3, 4 
Despite the bioavailability of GTCs being low following an oral dose, it can be 
enhanced under certain conditions, such as supplementing in a fasted state or repeat 
administration.33 Other HILI risk factors which have been suggested as contributors 
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to GTE hepatotoxicity include individuals taking concomitant medications, 
consumption of high doses, and gender, with females developing liver damage from 
this supplement more frequently than males.3, 4 Additionally, with growing evidence 
that certain polymorphisms in genes encoding CYP450, UGT and reactive oxygen 
species (ROS)-detoxifying enzymes increase the risk of HILI, along with particular 
MHC class I and II genotypes, the possibility of a genetic basis for the development 
of GTE-induced liver damage in certain individuals cannot be ruled out.86 
A number of weight loss products containing GTE have been associated with 
hepatotoxicity and liver failure, examples of which include Hydroxycut, Exolise and 
SlimQuick.78, 79, 87-89 Hydroxycut has a long history of being associated with 
hepatotoxicity, with more recent events believed to be due to its GTE content; since 
this was uncovered, Hydroxycut products no longer contain GTE as an ingredient.2, 
77, 87 Exolise and SlimQuick are weight loss products containing GTE which have also 
been implicated in cases of liver damage.78, 79, 88, 89 The sale of Exolise was banned in 
France and Spain in 2003 due to its association with 13 adverse reactions since 1999, 
one of which resulted in an individual requiring a liver transplant, which prompted 
the manufacturer Arkopharma to withdraw the product from the market 
worldwide.88 In both Exolise- and SlimQuick-induced liver damage, GTE was 
determined to be the most likely cause.78, 79, 88, 89 The acute liver injury associated 
with these products typically manifests in a hepatocellular manner, which is 
consistent with GTE-induced hepatotoxicity.78, 79, 89 
Over 50 cases of hepatotoxicity believed to be linked to the consumption of green 
tea or GTE have been reported in the literature over the last 20 years.3, 4 Whilst some 
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of these cases were due to weight loss products such as those outlined above, others 
were the result of other supplements which either contained GTE as one of a number 
of constituents or from the consumption of green tea or GTE in isolation.3, 4 
1.3.4.1 Cases of GTE-induced liver injury 
In England, 2015, it was reported that a 16-year-old girl suffered acute liver damage 
in response to Chinese green tea purchased via the internet.90 It was concluded that 
green tea was the culprit after ruling out all other possibilities, such as pregnancy, 
alcohol, “over-the-counter” medications and illicit drugs, nor had she recently 
received a blood transfusion.90 Acute hepatitis, viral hepatitis, autoimmune hepatitis, 
Wilson’s disease, haemochromatosis, a-1-antitrypsin deficiency and rare portal vein 
disturbances, such as Budd-Chiari syndrome, were also excluded.90 The patient did 
not immediately divulge her consumption of the green tea, which was purchased in 
a bid to lose weight.90 With intravenous fluids and treatment with N-acetylcysteine, 
the observed hepatitis completely resolved soon after discontinuing green tea 
consumption.90 
In Italy, 2007, a 51-year-old woman presented with a long-term history of abnormal 
liver function tests, specifically elevated serum aminotransferases, g-glutamyl-
transpeptidase and alkaline phosphatase, with histological examination showing 
mild cholestasis.91 Cessation of oestrogen and progestogen treatment following a 
hysterectomy did not rectify her liver function results, and tests for viral hepatitis, 
sclerosing cholangitis and primary biliary cirrhosis were negative.91 It was uncovered 
that, for at least 5 years, the patient had been consuming green tea every day and, 
when green tea consumption was ceased, the patient’s liver function tests began to 
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normalise within two months.91 The individual rechallenged her system with green 
tea six months later and there was a marked increase in serum aminotransferases, g-
glutamyl-transpeptidase and alkaline phosphatase in response; again, these liver 
function tests returned to normal following cessation of green tea consumption.91 
Interestingly, the patient’s 20-year-old daughter also had abnormal liver function 
tests which normalised after she discontinued drinking green tea, suggesting that 
there may be a genetic element in determining the susceptibility of an individual to 
green tea-induced liver injury.91 
A third example from 2017 involves a 50-year-old woman who presented at a 
hospital in the USA with abnormal liver parameters and symptoms of liver damage.82 
A liver biopsy demonstrated severe hepatic necrosis, however laboratory tests were 
negative for autoimmune hepatitis, hepatitis A, B, C and E, human immunodeficiency 
virus, herpes simplex virus, Wilson’s disease and a-1-antitrypsin deficiency.82 When 
questioned further by the medical practitioner, the patient disclosed that she had 
been consuming Vital Stem, an over-the-counter nutritional supplement containing 
GTE, for the last month.82 Having ruled out all other likely causes, it was determined 
that GTE was the ingredient most likely to be the cause of the observed acute liver 
injury.82 Following treatment with prednisone and cessation of Vital Stem 
supplementation, the patient’s condition improved over time.82 
In 2016 it was reported that a 26-year-old man from Western Australia presented 
with liver damage so severe that he was given two weeks to live without a 
transplant.45, 92 The ABC reported that the only compatible liver that became 
available during this time was infected with hepatitis B, thus, in order to survive the 
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man must now live the rest of his life with this disease.92 This is not the only instance 
in which GTE-induced hepatotoxicity has been reported in the media; in 2014 the 
BBC reported that when a 50-year-old man from England took GTE as part of an effort 
to lose weight, he was admitted to hospital approximately two to three months after 
commencing the supplementation and diagnosed with acute liver damage so severe 
he was given only days to live, thus also requiring a transplant.93 
Despite the differences between products consumed in the cases outlined, a process 
of elimination was employed by which GTE was determined to be the most probable 
cause in each.45, 82, 90-93 The idiosyncratic, acute onset characterised by a 
hepatocellular pattern of injury is typical of GTE-induced liver damage, and is 
observed repeatedly throughout the case reports in the literature.3, 4 It appears to be 
predominantly females who are affected and most, but not all, cases are associated 
with individuals endeavouring to lose weight.3, 4 
1.3.4.2 Mechanisms of GTE-induced hepatotoxicity 
GTE products may differ depending on the preparation procedure: aqueous extracts 
tend to contain predominantly hydrophilic components, whereas hydroalcoholic 
extracts contain both hydrophilic and hydrophobic compounds.94 Given that 
catechins are polar compounds, they are retained in both types of extract, however 
it has been found that they are present in higher concentrations in hydroalcoholic 
preparations.94 This could indicate that it is the catechins, particularly EGCG due to 
its abundance, that are responsible for GTE-induced liver damage.3 So far, the 
majority of research into GTE hepatotoxicity has been carried out using animal 
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models, predominantly with mice and rats, with many primarily focusing on EGCG.40, 
46, 95, 96 
It has been found that, at toxic doses, EGCG is metabolised to EGCG-2’’-cysteine and 
EGCG-2’-cysteine in mice.97 There is speculation that this may be due to EGCG being 
oxidised to a quinone or semiquinone, which goes on to react with the sulfhydryl 
group of cysteine and potentially other cysteine-containing molecules such as 
glutathione (GSH).97 
A 2006 study found that GTE-induced cytotoxicity is associated with GSH depletion 
and the formation of ROS, with GSH-depleted hepatocytes exhibiting greater 
susceptibility to EGCG toxicity.98 The same study also demonstrated that inhibition 
of NADPH:quinone oxidoreductase 1 (NQO1) is linked to increased ECG cytotoxicity 
and inhibition of COMT is associated with increased EGCG cytotoxicity and ROS 
formation.98 It has also been determined that polyphenols may have pro-oxidant 
properties, believed to be associated with the gallic acid component, with EGCG 
having been demonstrated to be the most cytotoxic and EC the least.98, 99 The 
production of ROS in response to EGCG and its metabolites has been suggested to 
lead to oxidative stress in liver cells, which may be responsible for the hepatocellular 
necrosis observed in certain individuals consuming GTE.3 Aside from ROS formation, 
collapse of the mitochondrial membrane and the subsequent dysfunction of 
hepatocyte mitochondria has also been suggested as a major mechanism of EGCG-
induced cytotoxicity.40 
GTE may also impact cellular respiration, with a 2015 study finding that EGCG reduces 
anaerobic glycolysis, glycolytic rate, glucose consumption and lactate production in 
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pancreatic carcinoma cells.100 This was followed by a 2016 study which reported 
similar findings using both in vitro and in vivo methods, with the results leading to 
the suggestion that EGCG promotes a shift from glycolysis in hepatocellular 
carcinoma cells by directly suppressing the activity of phosphofructokinase, and 
ultimately results in apoptosis due to metabolic stress.101  
In 2017, a number of biochemical changes were found to occur in rats following GTE 
treatment for one month, including increased levels of alanine aminotransferase, 
aspartate aminotransferase and malondialdehyde (MDA) and decreased GSH levels 
and hepatic catalase activity.46 Increased MDA and aminotransferases are indicative 
of oxidative stress and liver damage, respectively; decreased GSH levels and hepatic 
catalase activity, antioxidants involved in detoxifying ROS, likely exacerbate these 
hepatotoxic processes.46 The observations made in the histological examination 
were consistent with the biochemical results, demonstrating that GTE had induced 
moderate centrilobular hepatic necrosis with interstitial haemorrhage and 
infiltration of inflammatory cells; findings consistent with previous research into GTE 
toxicity using rat and mouse models.46, 102 
Whilst there is a clear link between GTE consumption and the subsequent 
development of liver damage in certain individuals, the causative compounds and 
mechanisms of injury remain speculative. GTE is composed of many potentially-
hepatotoxic compounds, and this is further complicated when the different 
metabolites formed from these constituents in vivo are considered.50, 51, 61 Given the 
accessibility and widespread use of GTE, a better understanding of how this 
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supplement induces hepatotoxicity is vital; metabolomics is one advanced technique 
which has shown promise in this field.5 
1.4 Analytical techniques 
1.4.1 Metabolomic analysis of hepatotoxicity 
Whilst traditional methods of toxicological analysis provide end-point results in 
assessing the toxicity of a given substance, they are unable to provide details on the 
mechanisms involved and any alterations in biochemical processes that occur.5 For 
example, a popular method of analysing in vitro toxicity involves the bioconversion 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), resulting in 
the production of NADPH which yields a colour change proportionate to the number 
of viable cells, known as the MTT assay.5, 103, 104 This provides information on the 
effect a substance has on cell viability, but no details about the mechanisms involved 
in any changes observed.5, 103, 104 Through the use of ‘omics’ techniques, which 
generate complex data representing cellular changes in response to a given trigger, 
it is possible to hypothesise the mechanisms by which a substance induces toxicity in 
the cell.5, 105 Metabolomics, a technique that provides insights into the biochemical 
profile of an organism, is a novel method for analysing in vitro hepatotoxicity.5, 105 
Given that changes in small molecules at the biochemical level of an organism 
represent the most downstream response to a stimulus, the metabolomic fingerprint 
allows for characterisation of the mechanisms involved in the toxicity of a substance 
in addition to the overall toxicological outcome.105 
For the in vitro metabolomic analysis of hepatotoxicity, HepG2 cells are the most 
commonly used cell model, likely due to their low variability and ready availability; 
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the primary setback associated with this cell line is their limited biotransformation 
capacity.5 The typical exposure timeframe used in in vitro metabolomic studies is 24 
h, and it is generally accepted that using five or more replicates provides the most 
reliable results, however as little as three can be adequate.5 The most common 
method of metabolomic analysis is chromatography coupled to mass spectrometry 
(MS), a hyphenated technique that has broad metabolite coverage and is highly 
sensitive and versatile.5 
Whilst liquid chromatography-MS (LC-MS) has been the most commonly used 
method for the in vitro metabolomic analysis of cytotoxicity, gas chromatography-
MS (GC-MS) is also capable of providing highly reproducible data in this field.5, 106, 107 
In addition to this, the libraries available for the identification of compounds by GC-
MS are comprehensive and easier to navigate than those used for LC-MS.108 This 
results in the more efficient and straightforward analysis of data generated via GC-
MS than for that produced via LC-MS. 
1.4.2 Chromatography 
Chromatography is a separation technique in which a sample is added to a mobile 
phase that is then passed through a stationary phase, with different analytes within 
the sample eluting from the stationary phase at different rates.106, 107, 109 There are 
two main types chromatography: liquid and gas, named after the state of the mobile 
phase.106, 107, 109 
In gas chromatography (GC), the mobile phase is an inert gas, such as helium; the 
role of the carrier gas, or eluant, is to aid in the movement of analytes from the inlet, 
through the column containing the stationary phase and into the detector.107 In order 
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for GC analysis to be effective, sample molecules must be volatile and stable enough 
to withstand the high temperatures in the GC oven; to ensure this, samples can be 
derivatised prior to injection in order to enhance the volatility and thermal stability 
of the compounds.110 Examples of compounds which require derivatisation include 
amino acids, saccharides and drugs.110 
There are a number of different ways in which a sample can be introduced into the 
GC inlet, and the application determines which type is best suited.107 Typically, 
injection involves the vaporisation of the sample in the inlet into a stream of carrier 
gas. For split injection, only a portion of the sample/carrier gas mixture is directed 
onto the GC column and the rest is expelled (Figure 1.3a).107 Alternatively, during 
splitless injection, the splitter vent is closed and thus the entire sample is directed 
onto the column (Figure 1.3b).107 This allows for concentration of the sample on the 
column for a period of time before the splitter vent is opened and the majority of the 
solvent is purged.107 The inlet is kept at a high temperature to ensure instantaneous 
vaporisation of the sample as it is introduced.106 
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Figure 1.3. The fate of sample molecules following split (A) and splitless injection (B).106 During a split 
injection the split vent is open, resulting in only part of the mixture of sample and carrier gas being 
directed onto the column.106 Alternatively, the split vent is closed during a splitless injection.106 This 
results in the sample being concentrated on the column for a set period of time prior to the split 
vent being opened to purge the majority of the solvent.106 
 
  
A) B) 
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The column, found inside the GC oven, is where separation of the sample molecules 
takes place.106 The column is typically composed of polysiloxane with a 5% 
diphenyl/95% dimethylsiloxane (5MS) stationary phase adhered to the inside 
surface.107 Sample molecules are carried onto the column by the eluant and become 
delayed by the stationary phase.107 The temperature inside the GC oven is gradually 
increased (4-20°C/minute), thus, sample molecules elute from the stationary phase 
at different times, depending on their boiling points.107 
As with methods of sample introduction, there are a wide variety of detectors 
available for GC analysis which may be universal, such as the flame ionisation 
detector (FID), or selective, such as the thermionic specific detector.107 In an FID, the 
sample compounds combust as they pass through a hydrogen flame, generating ions 
and electrons that cause a current flow, producing a signal which is recorded as a 
peak on the chromatogram.107 
1.4.3 Mass spectrometry 
MS is a technique used to separate charged particles within a sample based on their 
mass-to-charge ratio (m/z).109, 111 In order for this to occur, sample molecules must 
carry a charge, thus prior to entering the mass analyser the sample passes through 
an ionisation source which ionises the particles via methods such as chemical (CI) or 
electron ionisation (EI).112 CI is considered a soft ionisation technique as particles 
leave the source charged but intact; EI is considered a hard ionisation technique as 
particles within the sample become fragmented during the process (Figure 1.4).112, 
113 
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In EI, electrons are released from a metal filament following sufficient electrical 
heating and accelerated to 70 eV through an electric field.112, 113 The electrons are 
attracted to an anode on the opposite side of the ionisation source, creating an 
electron beam that travels perpendicular to the sample path.113 As the sample is 
introduced into the ionisation source it passes through this electron beam and the 
electrons transfer some of their energy to the molecules, generating charged product 
ions mostly via electron ejection.112, 113 An excess internal energy of 6 eV in the 
sample molecules is sufficient to cause reproducible fragmentation; this 
fragmentation pattern can be beneficial in the identification of compounds.112, 113 
Once formed, the product ions leave the ionisation source and are directed into the 
mass analyser.113 
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Figure 1.4. Overview of electron ionisation; where “e-“ represents energised electrons, “N” represents 
neutral molecules and “+” represents charged molecules.109, 111 Samples must pass through an 
ionisation source to ensure the analyte particles carry a charge prior to entering the mass analyser.109, 
111 During electron ionisation, electrons are released from a metal filament, accelerated to 70 eV and 
attracted to an anode on the opposite size of the ionisation chamber, creating an electron beam that 
travels perpendicular to the sample path.109, 111 As the analyte vapour is introduced into the ionisation 
source, electrons transfer energy to the molecules as they pass through the electron beam, generating 
charged product ions.109, 111 These product ions then leave the ionisation source and directed onto the 
mass analyser.109, 111 
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The mass analyser is responsible for the separation of molecules according to their 
m/z. Here, product ions are held until the appropriate m/z is scanned, allowing them 
to move through to the ion detector and be recorded.109 There are a number of 
different mass spectrometers, which differ in their method of separation and 
robustness. Examples include single quadrupole (Q), ion trap, triple quadrupole 
(QQQ) and quadrupole time-of-flight (QTOF) mass analysers.111 
Prior to entering the high-vacuum environment of a Q analyser, product ions are 
condensed into a stream by a series of lenses which use varying voltages to draw out 
and direct the ion beam to the quadrupole .109 The Q analyser uses direct-current 
(DC) and radiofrequency (RF) fields to individually screen the various m/z in a given 
sample.109, 111 The quadrupole itself consists of four longitudinally parallel quartz rods 
clamped in a pair of ceramic collars, with a hyperbolic cross-section between 
diagonally-opposed rods that is crucial for the operation of the mass analyser (Figure 
1.5).109 The DC and RF signals are applied across the rods, with adjacent rods having 
opposite charges.109, 111 Each set of DC and RF voltages is specific for ions of a 
particular m/z, which then follow a stable path through the centre of the quadrupole 
to the detector; all other ions of different m/z collide with the rods and cannot 
traverse the length of the quadrupole.109, 111 Typically, minimum and maximum m/z 
are established prior to analysis, and the entire mass spectrum within this range is 
scanned by changing the voltages applied to the rods.111
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Figure 1.5. Overview of a single quadrupole mass analyser.111, 112 A series of focusing lenses direct the sample ions to the quadrupole mass analyser, which consists 
of four longitudinally parallel rods and has a hyperbolic cross-section between the diagonally opposing rods that is crucial for its operation.111, 112 The mass analyser 
uses oscillating direct-current (DC) and radiofrequency (RF fields to individually screen the various mass to charge ratios (m/z) in a given sample.111, 112 Each set of 
DC and RF frequencies are specific to ions of a particular m/z, resulting in only one m/z species being able to follow a stable trajectory through the quadrupole at 
a given point in time.111, 112 Mismatched m/z species collide with the rods and are unable to traverse the length of the quadrupole.111, 112 
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A variation of the quadrupole mass analyser is the QQQ, which comprises three 
consecutive quadrupoles: the first (Q1) is used to select for a precursor m/z 
corresponding to the ion of interest, the second (Q2) uses a collision gas such as argon 
to dissociate that species into fragments, and the third (Q3) scans a pre-set m/z range 
to produce a product ion spectrum (Figure 1.6).112 QQQ is a form of tandem mass 
spectrometry (MS/MS), however it can also operate in full scan mode, in which Q1 
scans the sample and the subsequent quadrupoles merely direct the ions to the 
detector.112 A voltage gradient lines the QQQ, generating a negative bias in order to 
draw positive ions into the analyser and through to the detector.111 
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Figure 1.6. Overview of a triple quadrupole mass analyser.111, 112 The triple quadrupole is a variation of the quadrupole mass analyser which comprises three 
consecutive quadrupoles (Q1, Q2 and Q3) and can function as a form of tandem mas spectrometry or set to full scan mode.111, 112 For tandem mass spectrometry, 
Q1 is used to select for a precursor mass-to-charge ratio (m/z) corresponding to the sample ion of interest, which then pass into Q2 where a collision gas is 
introduced that dissociates the sample ions into fragments.111, 112 Finally, the resulting product ions enter Q3 where they are scanned over a m/z range to produce 
a product ion spectrum.111, 112 When set to full scan mode, Q1 scans the sample over a pre-set m/z range and the subsequent quadrupoles simply direct the sample 
ions to the detector.111, 112
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1.5 Concluding statements and aims 
Due to the complex composition of GTE, toxicological assays are unable to provide 
sufficient information in regards to which components may be responsible for the 
hepatotoxicity certain individuals experience in response to this supplement, nor do 
they aid in establishing the mechanisms by which the toxic compounds act. Currently, 
the role metabolites of GTE play in the development of hepatotoxicity in certain 
individuals is also poorly understood. By using untargeted metabolomic analysis, it 
will be possible to characterise the metabolites of GTE, as well as identify any 
biochemical changes in hepatocytes following exposure to these compounds. If 
cytotoxicity occurs, the biochemical changes observed could provide valuable insight 
into the mechanisms of toxicity associated with GTE consumption. Identifying these 
pathways will enable future studies to further identify which metabolites, if any, 
contribute to the manifestation of liver damage in certain individuals following 
consumption of GTE.  
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The primary aim of this study is to identify the biochemical changes in liver cells 
caused by exposure to GTE and its metabolites. This will be done by: 
 
• Exposing HepG2 cells to GTE, paracetamol and isolated catechins for 
24 h and analysing cell viability with the MTT cytotoxicity assay. 
 
• Metabolising GTE with S9 human liver fraction and characterising the 
resulting metabolites using untargeted GC-MS analysis. 
 
• Exposing HepG2 cells to GTE and its metabolites for 24 h and 
harvesting cells post-exposure to identify biochemical changes that 
have occurred via untargeted GC-MS analysis. 
 
• Exposing HepG2 cells to GTE and paracetamol for 24 h and harvesting 
cells post-exposure to identify biochemical changes that have 
occurred via untargeted GC-MS analysis. 
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2. Materials and methods 
2.1 Green tea extract and chemicals 
Green tea extract (GTE) was purchased online in powdered form. The catechin 
standards catechin hydrate (CH), epicatechin (EC), epigallocatechin (EGC) and 
epigallocatechin-3-gallate (EGCG) were purchased from Sigma-Aldrich (Sydney, 
Australia) at the highest available purity, as were glutathione (GSH), paracetamol 
(APAP), 3’-phosphoadenosine-5’-phosphosulfate (PAPS), magnesium chloride 
(MgCl2), reduced nicotinamide adenine dinucleotide phosphate (NADPH), phosphate 
buffered saline (PBS), S9 pooled human liver fraction and uridine 5’-
diphosphoglucuronic acid (UDPGA). Dulbecco’s Modified Eagle Medium (DMEM), L-
glutamine, heptane, methoxyamine hydrochloride, n-alkanes (C10, C12, C15, C19, C22, 
C28, C32 and C36), n-methyl-n-(trimethylsilyl) trifluoroacetamide (MSTFA), 
penicillin/streptomycin solution, 0.25% trypsin-ethylenediaminetetraacetic acid 
(EDTA) solution and pyridine were also purchased in the purest forms available from 
Sigma-Aldrich. Carbon dioxide (CO2) and helium were sourced from BOC (Sydney, 
Australia). Foetal calf serum (FCS), used to supplement the cell culture medium, was 
sourced from Serana (Bunbury, Australia). Methanol (> 99.9%), LC-MS grade 
acetonitrile (99.9%) and LC-MS grade water were sourced from Fisher Scientific (Fair 
Lawn, USA). Dimethyl sulfoxide (DMSO) was purchased from VWR Chemicals 
(Pennsylvania, USA). Corning Costar 6- and 96-well plates were sourced from Sigma-
Aldrich. 
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2.2 Cell preparation 
2.2.1 Cell culture 
HepG2 human hepatocarcinoma cells were purchased through Sigma-Aldrich from 
the European Collection of Cell Cultures. HepG2 cells were cultured in 75 cm2 flasks 
with Dulbecco’s Modified Eagle Medium (DMEM) which was supplemented with 1% 
L-glutamine, 1% penicillin and streptomycin and 10% FCS. Cells were incubated at 
37°C and 5% CO2 in a humidified Thermo Scientific Heraeus BB15 Function Line 
incubator and the medium was changed every 48 h. All cell culture work was carried 
out in an aseptic environment with equipment and surfaces being treated with 
ethanol and UV light. Cultures were grown to 80-90% confluence prior before being 
passaged or used for experimentation. The passaging of cells involved removal of the 
media, followed by the addition of 5 mL of PBS to wash the cells. PBS was removed 
and 2 mL of 0.25% trypsin-EDTA solution was added to dislodge the cells from the 
flask. Cells were incubated with the trypsin solution for 5 min, after which they were 
dislodged by gently tapping the flask. To inactivate the trypsin, 8 mL of fresh 
supplemented DMEM was added, in which the cells were resuspended until evenly 
distributed. For each new flask, 1 mL of this cell suspension was aliquoted and made 
up to 10 ml with fresh supplemented DMEM in order to yield a 1:10 passage. 
Passages 30, 31, 34 and. 36 were used in this study. 
An Olympus IMT-2 inverted microscope (Tokyo, Japan) was used to check the cells 
approximately every 48 h. To compare differences in growth and morphology of 
treated cells to untreated controls, cell photographs were taken using an Olympus 
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CKX41 microscope linked to a Moticam 2300 camera (Motic Instruments Inc., Hong 
Kong) using Motic Images Plus v2.0. 
2.2.2 Cell counts 
Cell counts were carried out to determine the concentration of cells; these were 
performed using the Trypan blue exclusion method both manually and using a 
NanoEnTek EVE automatic cell counter (Seoul, Korea). Non-viable cells take up the 
Trypan blue dye due to a loss of membrane integrity and thus have a blue 
appearance; viable cells appear white as they do not take up the dye.114 In addition 
to providing the concentration of total, live and dead cells, the EVE automatic cell 
counter also determines percentage cell viability. To perform a cell count using a 6-
well plate, the medium was removed from each counting well and replaced with 1 
mL of PBS to wash the cells. This PBS was subsequently removed and the wash step 
was repeated. Cells were then pre-treated with 500 µL of 0.25% trypsin-EDTA 
solution for 10 s, following which the trypsin was removed and 500 µL of fresh trypsin 
was added to the well and distributed evenly across the cells. The plate was then 
incubated at 37°C and 5% CO2 for 5-8 min to encourage trypsin activity. Once the 
cells were dislodged from the bottom surface of the well, 1.5 mL of fresh medium 
was added to neutralise the trypsin and cells were resuspended by pipetting until 
evenly distributed. 100 µL of this cell suspension was transferred into a new 
microcentrifuge tube and mixed with an equal volume of 0.4% Trypan blue. The 
concentration of cells was calculated by adding 10 µL of this cell suspension/Trypan 
blue solution to an EVE cell counting slide for analysis with the EVE automatic cell 
counter and a Hausser Scientific Bright-Line Haemocytometer for manual cell counts. 
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Cell counts determined manually were found to be more accurate for high cell 
concentrations and thus were used to determine the volume required for seeding 6- 
and 96-well plates. Cells were counted using the centre square, subdivided into 4 x 4 
smaller squares, with cells bordering the left and upper sides included, and those on 
the lower and right borders excluded. Counts were used to determine the 
concentration as cells/mL. Conversely, cell counts obtained using the EVE automated 
cell counter were found to be more reliable at determining lower cell concentrations, 
so were therefore used for well counts following cell exposures. Despite their 
difference in use, both methods were performed for every cell count in order to 
validate any changes observed in cell number. 
2.3 GTE effect on cell viability 
2.3.1 Extraction of GTE 
GTE, CH, EC, EGC, EGCG and APAP were extracted in serum-free DMEM. These 
solutions were then diluted with additional serum-free DMEM to obtain the 
concentrations outlined in the following section. 
2.3.2 MTT cytotoxicity assay 
At confluence, HepG2 cells at passage 34 were seeded at a density of 1.2 x 105 
cells/well in six 96-well plates with supplemented DMEM added to a total volume of 
200 µL, with the wells around the perimeter of each plate being excluded, along with 
wells B2-G2 and B11-G11. The plate allocated to the APAP treatment group received 
100 µL of DMEM + rifampicin prepared as outlined in section 2.4.1 to stimulate 
CYP450 activity. Finally, all empty wells around the perimeter of the plates received 
200 µL of DMEM in order to limit the possibility of edge effect impacting the sample 
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wells. All six plates were subsequently incubated at 37°C and 5% CO2 for 48 h to settle 
and adhere to the bottom surface of the wells. At the conclusion of the incubation 
period, spent medium was removed from the wells containing cells and replaced with 
100 µL of treated serum-free DMEM, with each concentration prepared in 12 
replicates. Each plate was allocated one of the following treatments: GTE, CH, EC, 
EGC, EGCG or APAP. Table 2.1 shows the concentrations used for each treatment 
type and their corresponding well numbers. 
 
Table 2.1 Concentrations of catechins (µM), GTE (mg/mL) and APAP (mM) and corresponding well 
designations used for the analysis of HepG2 cell viability with the MTT cytotoxicity assay.  
Concentration 
 B3-G3 
B4-G4 
B5-G5 
B6-G6 
B7-G7 
B8-G8 
B9-G9 
B10-G10 
CH 0 25 50 100 
EC 0 25 50 100 
EGC 0 25 50 100 
EGCG 0 25 50 100 
GTE 0 0.1 0.5 1.0 
APAP 0 7.5 15 30 
 
Following cell treatment and a 24-h exposure period, cell viability was measured 
using the Promega CellTiter 96 Non-Radioactive Cell Proliferation Assay. This 
colorimetric assay provides a measure of cell viability by the addition of a dye 
solution containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) to culture wells which viable cells reduce, forming an insoluble blue formazan 
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product.103, 104 The subsequent addition of a solubilising stop solution containing an 
organic solvent, which stops the conversion of the tetrazolium salt and solubilises 
the formazan product, creates an evenly coloured solution of which the absorbance 
may be measured to determine cell viability.103, 104 The colour intensity is 
proportional to the number of live cells, with a decrease in absorbance 
corresponding to a decrease in cell viability.103, 104 
15 µL of Promega dye solution was added to each well and plates were subsequently 
returned to the incubator for 4 h. Following incubation, 100 µL of Promega 
solubilisation solution/stop mix was added to each well and plates were left 
overnight at room temperature in a humid environment. A Tecan Spark 10M 96-well 
plate reader (Männedorf, Switzerland) was used to measure absorbance, with the 
device set to shake the plates for 5 s prior to reading in order to form an evenly 
coloured solution. The absorbance was read at 570 nm for each well, with the 
reference wavelength set to 660 nm to reduce background interference caused by 
inconsistencies such as cell debris or fingerprints. An overview of the procedure 
followed to prepare for and carry out the MTT assays is depicted in Figure 2.1. 
The MTT assay was repeated for the GTE treatment using cells at passage 36, with 
spent medium removed from wells and replaced with fresh serum-free DMEM prior 
to the addition of the dye solution. Additionally, six control wells were prepared by 
adding 100 µL serum-free DMEM to wells B2-G2, which did not contain cells, 
followed by the addition of 15 µL dye solution and incubation for the same 4 h period 
as the sample wells. 100 µL solubilisation solution/stop mix was then added to all six 
wells, which were also left overnight at room temperature. The absorbance of the 
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cell-free controls was read at 570 nm, with the mean subsequently calculated and 
subtracted from the values obtained for the sample wells in order to remove 
background absorbance caused by components in the medium and Promega 
solutions. 
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Figure 2.1. Overview of the workflow followed for the analysis of HepG2 cell viability using the MTT 
cytotoxicity assay. Created with BioRender.com.  
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2.4 Hepatotoxicity of GTE constituents and metabolites 
2.4.1 Metabolism of GTE 
GTE was metabolised using pooled human liver S9 fraction, which contains Phase I 
and Phase II enzymes, following the method outlined by Richardson et al.115 NADPH 
was used as a cofactor to activate Phase I metabolism and GSH, UDPGA and PAPS 
were used to stimulate Phase II enzymes. Individual stock solutions of NADPH, GSH, 
UDPGA and PAPS were prepared at concentrations of 34, 31, 13 and 1.6 mg/mL, 
respectively.115 These cofactor solutions were mixed in a 1:1:1:1 ratio to yield a 
solution with final concentrations of 0.85, 0.78, 0.33 and 0.04 mg/mL, respectively.115 
GTE was extracted with sterile water at a concentration of 100 mg/mL. 
PBS was prepared as a solution containing 2 mM MgCl2; the PBS maintains the 
reaction pH at 7.4 and the magnesium ions stimulate cytochrome P450 (CYP450) 
activity.115 140 µL of the 2 mM MgCl2/PBS solution was then aliquoted into 1.5 mL 
tubes, followed by the addition 20 µL of S9 liver fraction and 20 µL of GTE 
extraction.115, 116 In total, 15 replicates were prepared and preincubated at 37°C for 
5 min. Reactions were initiated by the addition of 20 µL of the cofactor mixture, 
yielding a final reaction volume of 200 µL and a GTE concentration of 10 mg/mL.115 
Samples were subsequently incubated at 37°C for 60 min, after which they were put 
on ice to quench the reactions. All samples were centrifuged for 10 min at 4.0 x 103 
rcf to remove the proteins, with centrifugation being carried out at 4°C in order to 
provide further quenching of metabolic reactions. Supernatant containing the GTE 
metabolites from each tube was subsequently pooled in a new 10 mL tube and stored 
at -80°C until required for cell exposures. 
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2.4.2 Cell treatment 
At confluence, HepG2 cells at passage 30 were seeded at a density of 1.0 x 106 
cells/well in 6-well plates with supplemented DMEM added to reach a total volume 
of 2 mL. The plates were subsequently incubated at 37°C and 5% CO2 for 48 h to allow 
cells to settle and adhere to the bottom surface of the wells. 
Six plates were prepared for the exposures: 2 x GTE metabolites (GTEM), 2 x 
unmetabolised GTE (GTE) and 2 x controls. The GTE metabolites produced in section 
2.4.1 were used to treat the cells in the GTEM plates. GTE was extracted with sterile 
PBS at a concentration of 10 mg/mL to treat the GTE plates. 
Following the 48-h incubation period, spent medium was removed from all wells and 
replaced with 1.8 ml serum-free DMEM. 200 µL of the appropriate treatment (GTEM 
or GTE) was then added to each well. The final concentration of GTE metabolites in 
the GTEM plates was equivalent to 1 mg/mL unmetabolised GTE. The GTE plates 
contained a final GTE concentration of 1 mg/mL, as this concentration was recently 
shown to induce significant toxicity in HepG2 cells.117 Cells in the control plates 
received 200 µL of sterile PBS. Plates were then returned to the incubator for a 24-h 
exposure period. 
At the conclusion of the exposure period, all 6-well plates were put on ice. A counting 
well was set aside on each plate to determine cell viability following the exposures, 
yielding 2 replicates of each sample type for cell counts, which were performed as 
outlined in section 2.2.2. The cells from the remaining 5 wells were harvested using 
a rubber cell scraper into 500 µL methanol containing 13C6-sorbitol internal standard 
at a concentration of 2.6 µg/mL. The contents of each well were transferred into 1.5 
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mL microcentrifuge tubes and put on ice in preparation for extraction of small 
molecule metabolites. In total, this yielded 10 replicates of each sample type for 
analysis via gas chromatography-mass spectrometry (GC-MS). 
An additional two plates were prepared in order to be pooled and used as quality 
controls (QCs) for GC-MS analysis. QC plates were seeded in the same manner as the 
sample plates and incubated at 37°C and 5% CO2 for 48 h. At the conclusion of this 
incubation period, cells were harvested from all wells as outlined above. 
2.4.3 Extraction of small molecule metabolites 
In order to release the small molecule metabolites for GC-MS analysis, it is essential 
to lyse the cell membrane and isolate them from the cellular material.118 Metabolites 
were extracted with a Bertin Technologies Precellys 24 Lysis and Homogenisation 
tissue lyser (Aix-en-Provence, France) at 6500 rpm for 2 x 20 s. The tubes were then 
centrifuged at 16.1 x 104 rcf for 5 min in an Eppendorf 5415R centrifuge (Sydney, 
Australia) to remove the cellular material, leaving the small molecule metabolites in 
the supernatant. 300 µL of supernatant from each sample was then transferred into 
new microcentrifuge tubes. Supernatant obtained from the QC samples was pooled 
in a 10 mL centrifuge tube prior to being aliquoted into new microcentrifuge tubes 
in 300 µL aliquots. All tubes were then spun in an Eppendorf Concentrator Plus rotary 
vacuum concentrator (Sydney, Australia) on the V-AL setting to remove the solvent. 
2.4.4 Metabolomic analysis 
2.4.4.1 Derivatisation 
Derivatisation was performed to chemically transform the compounds in the samples 
in order to ensure they were thermally stable and sufficiently volatile, thus increasing 
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the number of compounds able to be detected via GC-MS analysis.118 Methoxyamine 
hydrochloride was dissolved in pyridine at a concentration of 20 mg/mL, and 20 µL 
of this solution was added to each dried sample. Samples were incubated at 30 °C 
using an Eppendorf Thermomixer Comfort (North Ryde, Australia) with agitation at 
1200 rpm for 90 min. Methoxyamine prepares the compounds for derivatisation by 
reacting with their carbonyl groups to form oxime derivatives that stabilise the 
compounds for derivatisation with MSTFA.110 Following incubation, 40 µL of MSTFA 
was added to each tube and the samples were incubated at 37°C with agitation at 
300 rpm for 30 min. During this incubation period, the MSTFA adds silyl groups to 
functional groups on the compounds in each sample, yielding a trimethylsilyl 
derivative.110 Due to the nature of these reactions, multiple derivatisation products 
for a given compound are possible.110 50 µL of each sample was transferred to 2 mL 
brown glass GC vials with 100 µL inserts. 5 µL of n-alkanes in heptane was added to 
each sample and the vials were capped. All sample vials were then loaded onto the 
GC-MS and left to react for 1 h prior to analysis. 
2.4.4.2 Instrumentation 
A Shimadzu GC-2010 Plus gas chromatograph coupled to a Shimadzu GCMS-QP2010 
single quadrupole mass analyser was used to perform untargeted metabolomic 
analysis following derivatisation. Samples were injected via a Shimadzu AOC-20i Auto 
Injector following 5 pre-injection methanol wash steps. The needle was rinsed with 
sample once prior to the 1 µL injection of the sample in splitless mode. This was 
followed by 5 post-injection wash steps with methanol. The temperature of the GC 
inlet was set to 250°C and lined with an SGE inlet liner (Trajan Scientific and Medical, 
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Melbourne, Australia). The carrier gas used was high purity helium, which was set to 
a total flow rate of 1 mL/min with the retention time locked to elute the C19 n-alkane 
at 30.34 min. The GC column was an Agilent VF-5MS column (length 39.5 m + 10 m 
EZ-Guard; internal diameter 0.25 mm; film thickness 0.25 µm). Initial oven 
temperature was set to 70°C and held for 1 min between samples to stabilise, then 
programmed to increase at a rate of 1°C/min for the first 6 min, after which this 
increased to 5.63°C/min until the final temperature of 330°C was reached and held 
for 10 min to allow time for the remaining analytes to elute from the column. The 
GC-MS interface was maintained at a temperature of 300°C and, following an 8-min 
solvent delay, eluting analytes entered the ionisation source which was set to 250°C. 
Within the ion source, analytes were ionised via electron ionisation with electrons 
energised to 70 eV. The quadrupole mass analyser had a scan range of m/z 50-1000 
and a scan rate of 10 scans/s. 
2.4.4.3 Data analysis 
GC-MS data was imported to AnalyzerPro v5.5.1 (SpectralWorks, Runcorn UK) and 
deconvoluted. The mass spectrum and retention index of individual spectra were 
searched and matched against the National Institute of Standards and Technology 
(NIST) Mass Spectral Library v2.3 to putatively identify unknown metabolites. Three 
match criteria were set for metabolite identification: 1) forward match score ≥650, 
2) reverse match score ≥650, and 3) probability ≥20%.119 To be considered a match, 
a given metabolite must have met a minimum of 2 of these 3 criteria. 
Raw data was exported to Microsoft Office Excel 2016 and normalised to the 13C6-
sorbitol internal standard and the average cell count for each sample type. 
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Compounds that were present in <70% of all samples were excluded from further 
analysis. The remaining normalised data was then imported to The Unscrambler X 
v10.3 (CAMO Software, Oslo, Norway) and transformed logarithmically using the 
formula x = log (x + 1). Unsupervised analysis was carried out using principal 
component analysis (PCA), followed by partial least squares – discriminant analysis 
(PLS-DA) as a form of supervised analysis to identify variation between the sample 
groups. PLS-DA X-loadings were used to identify which metabolites most contributed 
to the variance observed between sample groups, using a threshold of +/- 0.05. 
IBM SPSS Statistics v24 was used to carry out statistical analysis on the data which, 
following a test for normality, was determined to be non-parametric. The Mann-
Whitney U test was used as a non-parametric equivalent to an independent t test for 
comparing results from the MTT assays. For analysing the GC-MS results obtained 
from cell exposures, the Kruskal-Wallis test was used as a one-way ANOVA to 
establish whether the metabolites differed significantly between the samples, and 
the pairwise output from this test was used to determine whether there was a 
significant difference between the overall metabolite profiles of the sample 
groups.120 A significance level of 5% was used for each test, along with a confidence 
interval of 95%.120 
Once the data analysis was complete, the metabolites were then mapped to 
biochemical pathways using the HMDB, SMPDB, MetaboAnalyst and KEGG databases 
in an effort to interpret the biological relevance of the observed changes in the 
treated cells.121-124 
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Figure 2.2. Overview of workflow followed for the analysis of hepatotoxicity following cell exposure 
to 1 mg/mL of GTE or GTE metabolites using GC-MS. Created with BioRender.com. 
 
2.4.5 Characterisation of GTE metabolites 
GTE was extracted with LC-MS grade water at two concentrations: 10 and 50 mg/mL. 
Isolated CH, EC, EGC and EGCG standards were individually prepared in LC-MS grade 
methanol, each at a concentration of 1 mg/mL. 
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GTE was metabolised in the same manner as outlined in section 2.4.1, except 
reactions were quenched by adding 200 µL of ice cold 50:50 methanol/acetonitrile 
to each tube.115 Catechin standards were also metabolised following the procedure 
in section 2.4.1, with the only difference being that 20 µL of a given standard was 
added instead of GTE. In total, 10 replicates were prepared for each of the two GTE 
concentrations and 3 replicates for each of the four catechin standards. The final 
reaction concentrations were 1 and 5 mg/mL for GTE and 0.1 mg/ml for each of the 
catechin standards. As in section 2.4.1, all GTE samples were centrifuged 
immediately after the reactions were quenched to remove the precipitated proteins, 
however the catechin samples were instead centrifuged following derivatisation. 
Supernatant was transferred into new microcentrifuge tubes, with samples kept 
separate. These tubes were then spun in an Eppendorf Concentrator Plus rotary 
vacuum concentrator on the V-AQ setting to evaporate the solvent. 
Two sets of controls were also prepared for this analysis: unmetabolised GTE extracts 
at two concentrations (0.1 and 0.5 mg/mL) and S9 reaction blanks. GTE was extracted 
with LC-MS grade water and 300 µL was aliquoted into new tubes in 3 replicates of 
each concentration. 10 replicates of S9 reaction blanks were prepared in the 
sequence outlined in section 2.4.1 and contained all constituents used for the 
metabolism except for the extracts of GTE or catechin standards. All controls were 
spun in an Eppendorf Concentrator Plus rotary vacuum concentrator on the V-AQ 
setting until the solvent was removed. 
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2.4.5.1 Metabolomic analysis 
All samples were derivatised following the procedure outlined in section 2.4.4.1 and 
GC-MS analysis was carried out using a Shimadzu GC-2010 Plus gas chromatograph 
coupled to a Shimadzu GCMS-QP2010 single quadrupole mass analyser with the 
parameters outlined in section 2.4.4.2, however the S9 controls and metabolised GTE 
samples were analysed in split mode with a split ratio of 20:1, due to their high 
concentrations. The GTE controls and metabolised catechin standards were 
subsequently analysed in splitless mode to account for their lower concentrations. 
GC-MS data was imported to AnalyzerPro v5.5.1 and deconvoluted. Raw peak areas 
for the identified compounds were exported as an Excel spreadsheet. The matrix was 
assessed manually and all components identified in the S9 and GTE controls, 
including catechins, were removed in order to isolate the GTE metabolites. Following 
this, compounds were retained if they were present in ≥70% of all samples to ensure 
reproducibility. In order to identify unknown metabolites, the spectra were matched 
to the National Institute of Standards and Technology (NIST) 2005 Mass Spectral 
library using the same criteria as outlined in section 2.4.4.3. Additionally, data 
obtained from the metabolised catechin standards were matched to the compounds 
in the metabolised GTE samples to tentatively confirm the presence of catechin 
metabolites. 
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Figure 2.3. Overview of GTE metabolite preparation and characterisation using GC-MS analysis. 
Created with BioRender.com.  
 57 
2.5 GTE and paracetamol-induced hepatotoxicity 
2.5.1 Rifampicin-induced CYP450 activity 
It has been demonstrated that rifampicin can induce CYP450 activity in HepG2 
cells.125 A 10 mM stock solution containing rifampicin dissolved in DMSO was diluted 
1:5 with PBS to yield a 2 mM working solution, which was subsequently filtered using 
a 0.2 µm filter to ensure sterility. 909 µL of this working solution was diluted in 49.091 
mL of supplemented DMEM containing 10% FCS, yielding a 36 µM DMEM + rifampicin 
solution for cell exposures.  
2.5.2 Cell treatment 
At confluence, HepG2 cells at passage 31 were seeded at a density of 1.0 x 106 
cells/well in 6-well plates with 1 mL DMEM + rifampicin and topped up with 
additional supplemented DMEM to reach a total volume of 2 mL/well. A total of 10 
plates were seeded and then incubated at 37°C and 5% CO2 for 48 h to allow cells to 
settle and adhere to the bottom surface of the wells. Following this incubation 
period, spent medium was removed from the wells and the treatment solutions were 
added to the appropriate plates as follows: 2 mL of serum-free DMEM containing 15 
mM APAP was added to the paracetamol (APAP) plates, 2 mL of serum-free DMEM 
containing 15 mM APAP and 1 mg/ml GTE was added to the APAP/GTE plates and 2 
mL of serum-free DMEM containing 1 mg/mL GTE was added to the GTE plates. These 
concentrations were chosen as 15 mM APAP has been demonstrated to reduce 
HepG2 cell viability by approximately 20%, and 1 mg/mL GTE was consistent with 
other exposure concentrations used in this project.26 Two plates were allocated to 
each treatment type and two were allocated to controls, in which the spent DMEM 
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+ rifampicin was replaced with fresh serum-free DMEM. These eight plates were then 
incubated at 37°C and 5% CO2 for 24 h. The remaining two plates were harvested at 
the conclusion of the initial 48 h incubation period in order to be pooled and used 
QCs for GC-MS analysis. 
At the conclusion of the exposure period, all 6-well plates were put on ice. A counting 
well was set aside on each plate to determine cell viability following exposure, 
yielding 2 replicates of each sample type for cell counts which were carried out 
following the method outlined in section 2.2.2. A rubber cell scraper was used to 
harvest the cells from the remaining 5 wells into 500 µL methanol containing 13C6-
sorbitol internal standard at a concentration of 2.6 µg/mL. The contents of each well 
were transferred into 1.5 mL microcentrifuge tubes and the small molecule 
metabolites were extracted following the procedure outlined in section 2.4.3. This 
yielded a total of 10 replicates of each sample type for GC-MS analysis. 
2.5.3 Metabolomic analysis 
Samples were derivatised following the procedure outlined in section 2.4.4.1, GC-MS 
analysis was carried out using a Shimadzu GC-2010 Plus gas chromatograph coupled 
to a Shimadzu GCMS-QP2010 single quadrupole mass analyser with the parameters 
outlined in section 2.4.4.2 and the data was analysed following the procedure 
outlined in section 2.4.4.3.  
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Figure 2.4. Overview of workflow followed to determine effect of GTE on paracetamol-induced 
hepatotoxicity using GC-MS analysis. Created with BioRender.com.  
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3. Results and discussion 
3.1 MTT cytotoxicity assay 
A decrease in cell viability was observed as paracetamol concentration increased 
(Figure 3.1). Cells treated with 15 and 30 mM APAP had lower mean absorbance than 
was observed in untreated cells, demonstrating a 12.92% (±	13.29%) and 19.1% 
(±	23.67) decrease, respectively. These results suggest a decrease in cell viability as 
APAP concentration was increased. An ED50 was unable to be calculated as it was not 
possible to determine the maximal response from the concentrations used in this 
study. Untreated controls had a relative standard deviation (RSD) of 17.08%, 
compared to 19.30%, 13.29% and 23.67% observed within the 7.5, 15 and 30 mM 
treatment groups. An RSD of <20% is generally an acceptable level of variation, and 
thus results within this range were considered reliable; only the 30 mM APAP sample 
group exceeded this limit. No significant difference in cell viability was observed 
between any of the treatment concentrations compared to untreated controls 
(p>.05).  
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Figure 3.1. Change in HepG2 cell viability following exposure to 0, 7.5, 15 and 30 mM APAP as 
measured by MTT assay (n = 12 for each concentration). Error bars indicate relative standard 
deviation.  
 
Absorbance appeared to increase with EGCG concentration, with 100 µM EGCG 
being 76.78% (±	13.05) higher than untreated controls (Figure 3.2). This pattern was 
also observed to varying degrees with the other catechins analysed, with the increase 
in mean absorbance most pronounced in cells treated with CH and EGCG. The least 
change was observed in cells treated with EGC, with 100 µM of this catechin having 
an absorbance that was 11.52% (±	18.69) higher than untreated controls. The 
majority of samples had an RSD <20%, except cells treated with 25 µM EGCG 
(26.61%) and untreated cells in the CH MTT assay (28.04%). 
The results for the catechin MTT assays are suspected to be abnormal as it was 
expected that cell viability, and therefore absorbance, would decrease as catechin 
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concentration increased. Spent DMEM and HepG2 cells had a dark brown 
appearance following catechin exposure, thus it is possible that this pigment may 
have interfered with the absorbance measurements obtained for the catechin 
exposures. 
 
 
Figure 3.2. Change in HepG2 cell viability following exposure to 0, 25, 50 and 100 µM EGCG, EGC, EC 
or CH as measured by MTT assay (n = 12 for each concentration). Error bars indicate relative standard 
deviation. 
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the conclusion of the exposure period; it is therefore likely that the absorbance 
values obtained here were also inaccurate. The RSD for untreated controls (20.31%) 
was higher than those observed in all three GTE treatment groups, with 0.1, 0.5 and 
1.0 mg/mL samples having 12.92%, 13.18% and 1.86% RSD, respectively. It is worth 
noting that due to the intensity of the colour change observed in 1 mg/mL GTE 
treatment wells, the plate reader was only able to record absorbance values for 3 of 
the 12 samples. This may explain the low RSD obtained for this treatment 
concentration compared to the others tested in this assay. 
 
 
Figure 3.3. Change in HepG2 cell viability following exposure to 0, 0.1, 0.5 and 1.0 mg/mL GTE as 
measured by MTT assay (n = 12 for each concentration except 1 mg/mL, for which n = 3). Error bars 
indicate relative standard deviation. 
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The GTE MTT assay was repeated with the same concentrations, however spent 
medium was replaced with fresh serum-free DMEM prior to the addition of the dye 
solution in an effort to limit background interference. A decrease in the overall trend 
was observed, although absorbance still appeared to increase with increasing GTE 
concentration, with cells exposed to 1 mg/mL GTE having an absorbance 25.43% 
(±	7.55) higher than that observed in untreated cells (Figure 3.4). This difference was 
markedly less than the increase of 118.01% observed between the same sample 
types in the original GTE MTT assay, and similar reductions were observed across the 
other GTE concentrations, suggesting that replacement of treated medium with fresh 
DMEM helped to reduce background absorbance. This assay had less variation within 
the untreated controls, 0.1 and 0.5 mg/mL sample groups than in the first GTE MTT 
assay, with RSDs of 5.23, 6.30 and 4.76%, respectively. Cells treated with 1 mg/mL 
GTE demonstrated greater variance compared to the first GTE MTT assay, although 
still within the acceptable range, with an RSD of 7.55%. The 0.5 and 1.0 mg/mL GTE 
had a mean absorbance significantly lower than the same concentrations in the 
original GTE MTT assay (p<.001). 
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Figure 3.4. Change in HepG2 cell viability measured by MTT assay following exposure to 0, 0.1, 0.5 and 
1.0 mg/mL GTE with spent medium replaced prior to addition of MTT dye solution (n = 12 for each 
concentration). Error bars indicate relative standard deviation. *Mean absorbance differed 
significantly compared to that recorded for the same treatment concentration in the first GTE MTT 
assay, as determined by the Mann-Whitney U test (p<.05). 
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Further development of this assay is required, and absorbance should be read from 
a set of control wells prepared at the same GTE concentrations, with the addition of 
solubilisation solution/stop mix but without the addition of dye solution. The 
purpose of including the solubilisation solution/stop mix is to retain the lysis and 
solubilisation step so the absorbance of the dark pigment may be properly measured. 
The mean of the absorbance values obtained from these controls could then be 
calculated and subtracted from the mean absorbance values obtained from sample 
plates that have been treated with dye solution. This would reduce interference from 
the brown pigmentation observed in HepG2 cells, providing more accurate 
measurements and potentially demonstrating the expected decrease in cell viability 
with increasing GTE concentration. 
3.2 Hepatotoxicity of GTE and its metabolites 
3.2.1 Cell density 
Microscopic examination of the cells post-exposure showed approximately 80% 
confluence across the bottom of the wells in the control samples (Figure 3.5). In 
comparison, approximately 50-60% confluence was observed in the wells containing 
the GTE- and GTE metabolite (GTEM)-treated samples. It was difficult to distinguish 
any difference between the cell number and viability of GTE- and GTEM-treated cells 
by microscopy alone. In both treatments the medium changed from pink to brown 
and the cells also took on a darker appearance, as observed in section 3.1.  
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Figure 3.5. Light microscope images at 100x magnification comparing untreated HepG2 cells (A) with 
those exposed to 1 mg/mL GTE (B) or 1 mg/mL GTEM (C) for 24 h. 
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The mean HepG2 cell concentration in untreated controls was 1.06 x 106 cells/mL 
(±	4.77 x 105), more than twice that observed in the treatment groups (Figure 3.6). 
Untreated cells had an RSD of 44.92%; this variation is likely explained by the loss of 
a large number of cells from one well during the PBS wash step, thus, the 
concentration of control cells is expected to have been higher than the mean 
described here. Given that only two wells were used for determining post-exposure 
cell concentration, with two cell counts from each, a higher number of wells should 
be used in future in order to more accurately determine a concentration of untreated 
cells. At the conclusion of the 24-h incubation period, GTE-treated samples had the 
lowest mean cell concentration at 3.75 x 105 cells/mL (±	7.07 x 104), whilst a mean 
of 4.40 x 105 cells/mL (±	1.34 x 105) was observed in the GTEM-treated samples. 
Greater variation was observed in the GTEM treatment group, which had an RSD of 
30.53%, compared to GTE-treated cells (18.86% RSD). Given that the GTEM-treated 
cells had an RSD >20%, the mean cell concentration determined for this treatment 
group is potentially unreliable. As with the untreated controls, it is possible that 
increasing the number of wells used for cell counts may aid in the reduction of 
variation within the GTEM treatment group. 
The decrease in mean cell concentration observed in the treatment groups may be 
indicative of hepatotoxicity, as these results are consistent with previous findings 
that high-doses of GTE elicit cytotoxicity in hepatocytes.95 Given that the degree of 
GTE metabolism was not determined prior to treating cells with GTEM, it is difficult 
to establish whether it was the metabolites or unaltered GTE constituents 
responsible for the cytotoxicity observed in GTEM-treated cells. Given that Phase II 
metabolism tends to render compounds relatively inert for excretion, the reduced 
 69 
toxicity observed in GTEM-treated cells in comparison to the GTE treatment group 
may be due to a decreased concentration of toxic precursors.18, 19 
HepG2 cells were difficult to trypsinise post-exposure to GTE and GTEM, potentially 
due to a reaction between the GTE and the well coating. This resulted in only 80-90% 
of the cells being successfully resuspended, thus the cell concentrations determined 
for these treatments may be underestimated. 
 
 
Figure 3.6. HepG2 cell concentration following exposure to 1 mg/mL GTE or 1 mg/mL GTEM for 24 h 
compared to untreated controls (n = 2 for each sample group). Error bars indicate standard deviation. 
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3.2.2 Metabolomic analysis 
The PCA scores plot generated to compare the three sample groups demonstrated a 
difference between GTE and GTEM-treated samples compared to untreated controls 
(Figure 3.7a). Principal component 1 (PC-1) explained 19% of the observed variance, 
whilst 17% was explained by principal component 2 (PC-2). Variance between the 
GTE- and GTEM-treated cells was unable to be determined from the PCA scores plots 
comparing these two sample groups (3.7b). 
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Figure 3.7. PCA scores plots using the first two principal components for comparisons of HepG2 cell 
metabolite profiles following treatment with serum-free DMEM containing 1 mg/mL GTE (green) or 1 
mg/mL GTEM (red) and untreated controls (blue), as measured by GC-MS analysis (n = 10 for each 
sample group). A difference in metabolite profile was observed between untreated cells compared to 
both treatment groups (A). A difference between GTE-treated cells and the GTEM treatment groups 
was unable to be determined via PCA (B). 
 
A) 
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A difference in metabolite profile was observed in the PLS-DA scores plot comparing 
the GTE and GTEM treatment groups (Figure 3.8). This difference was primarily 
explained by factor-1, with 10% and 71% of the observed variance explained. 
 
 
 
Figure 3.8. PLS-DA scores plot using the first two principal components (factors) for comparison of 
HepG2 cell metabolite profiles following exposure to 1 mg/mL GTE (green) or 1 mg/mL GTEM (red) 
for 24 h, as measured by GC-MS analysis (n = 10 for each sample group). Using PLS-DA, a difference 
was distinguished between the metabolite profiles of GTE-treated cells compared to the GTEM 
treatment group. 
 
Using PLS-DA X-loadings and a threshold of +/- 0.05, 42 compounds contributing 
most to the variance observed between sample groups were identified (Figure S1). 
22 of these were putatively identified after meeting at least 2 of the 3 match criteria 
outlined in section 2.4.4.3 when compared to the NIST library. Following the removal 
of compounds deemed likely to be solvent-derived, 18 metabolites remained. 
Comparing these 18 metabolites, a significant difference was observed between the 
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profiles of untreated controls compared to GTE-treated cells (p<.001), and also 
between the controls and GTEM treatment group (p=.001) (Figure S2). The 
metabolite profile of GTE-treated cells was not found to significantly differ from that 
of the GTEM treatment group (p=.446). Of the 18 metabolites, 15 demonstrated a 
positive fold-change (>1.0) in mean peak area size in both treatment types compared 
to those derived from control samples (Table 3.1). A negative fold-change (<1.0) was 
observed in the remaining 3. All metabolites were found to differ significantly 
between sample groups, with the exception of D-phenylalanine, serine and L-
glutamine. 
Gallic acid, 9-octadecanoic acid, an unidentified short-chain fatty acid, palmitic acid, 
citric acid and 5,8,11-eicosatrienoic acid demonstrated changes >10-fold in both 
treatment types, listed here in decreasing magnitude of change observed in GTE-
treated cells. Palmitelaidic acid and an unidentified piperidine derivative had a 
change >10-fold in GTE-treated samples only; neither of these metabolites were 
identified as contributing substantially to the variance observed between GTEM 
samples and untreated controls. L-5-oxoproline had a change >10-fold in GTEM-
treated samples and also contributed to the difference in metabolite profile 
observed between GTE-treated cells and controls. Only 3 metabolites demonstrated 
a negative fold-change, all of which were amino acids: L-glutamine (GTEM: 0.93), L-
glutamic acid (GTE: 0.52) and glycine (GTE: 0.40, GTEM: 0.47). Of the amino acids, 
carbohydrates and fatty acids, the greatest fold-changes were observed in L-5-
oxoproline (GTE: 8.47, GTEM: 10.38), myo-inositol (GTE: 5.35, GTEM: 7.91) and 9-
octadecanoic acid (GTE: 32.05, GTEM: 21.30), respectively.  
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Table 3.1. Fold change observed in metabolites of HepG2 cells post-exposure to 1 mg/mL GTE or 1 
mg/mL GTEM compared to untreated controls, as measured by GC-MS analysis (n = 10 for each sample 
group). Changes were primarily observed in amino acids and fatty acids. Green arrows indicate a 
positive-fold change compared to untreated controls and red arrows indicate a negative fold-change. 
*Metabolite differed significantly between sample groups, as determined by the Kruskal-Wallis test 
(p<.05). 
Metabolite GTE GTEM 
Amino acids 
L-5-Oxoproline* ­ 8.47 ­ 10.38 
L-Isoleucine* ­ 4.95 ­ 5.03 
DL-Phenylalanine ­ 2.96 ­ 3.93 
Serine - ­ 1.14 
L-Glutamine - ¯ 0.93 
L-Glutamic acid* ¯ 0.52 - 
Glycine* ¯ 0.40 ¯ 0.47 
Carbohydrates 
Myo-Inositol* ­ 5.35 ­ 7.91 
Unidentified carbohydrate* - ­ 3.58 
Fatty acids 
9-Octadecanoic acid* ­ 32.05 ­ 21.30 
Unidentified short-chain fatty acid* ­ 27.57 ­ 28.72 
Palmitic acid* ­ 23.02 ­ 18.70 
5,8,11-Eicosatrienoic acid* ­ 16.65 ­ 15.23 
Palmitelaidic acid* ­ 15.75 - 
Other metabolites 
Gallic acid* ­ 52.58 ­ 54.88 
Citric acid* ­ 16.76 ­ 26.22 
Unidentified piperidine derivative* ­ 12.30 - 
Uracil* ­ 6.25 - 
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L-5-oxoproline, a cyclised L-glutamic acid derivative also known as pyroglutamic acid, 
is an intermediate in the g-glutamyl cycle, the pathway in which glutathione is 
biosynthesised and metabolised.122, 124 Glutathione is a non-enzymatic free radical 
scavenger which can become depleted during oxidative stress; this may result in the 
accumulation of intermediates of the g-glutamyl cycle, including L-5-oxoproline.126 
Additionally, L-5-oxoproline can induce acidosis and other adverse health effects at 
sufficiently high concentrations.121 It is possible that the observed positive fold-
change in L-5-oxoproline is an indication that cells from both treatment groups were 
under oxidative stress.  
A negative fold-change was observed in glutamine, glutamic acid and glycine; this 
may indicate their consumption as an alternative energy source, potentially due to a 
fault in the glycolytic pathway.122 Conversely, the amino acids isoleucine, 
phenylalanine and glycine demonstrated a positive fold-change. This could be 
indicative of protein degradation or a malfunction in protein synthesis, either of 
which could cause an elevation of free amino acids within the cells. GTEM-treated 
cells demonstrated a positive fold-change in serine; it has previously been found that 
serine has an antioxidant function, therefore a positive fold-change in this amino acid 
could be due to its mobilisation in response to a pro-oxidant state within the cells.127  
An unidentified carbohydrate demonstrated a positive fold-change, which may be 
indicative of a malfunction in the glycolytic pathway that has potentially reduced 
cellular ability to use carbohydrates as an energy source.122 Alternatively, it could 
indicate that treated cells lost their capacity to convert non-glucose carbohydrates 
into glycolysis-compatible compounds. Either of these suggestions could explain the 
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requirement for alternative energy sources, such as amino acids, in order for cells to 
continue generating energy whilst bypassing glycolysis.  
A positive fold-change was also observed in myo-inositol, a key structural component 
of the inositol phosphate secondary messengers which are involved in a variety of 
cell signalling pathways.128, 129 Of note, inositol phosphate controls intracellular 
calcium ion (Ca2+) concentration; in hepatocytes, type I inositol 1,4,5-triphosphate 
receptor (InsP3 R-I)-mediated Ca2+ signalling is involved in triggering the early phase 
of liver regeneration.128 Additionally, it has been suggested that inositol-requiring 
enzyme-1a (IRE1a), an endoplasmic reticulum transmembrane protein, may also 
promote liver regeneration via regulation of the signal transducer and activator of 
transcription 3 (STAT3) pathway, which has a role in hepatocyte proliferation during 
the regenerative response.129 It is therefore possible that the positive fold-change 
observed in myo-inositol in cells treated with GTE or GTEM may be due to increased 
inositol requirement within the cells in an attempt to initiate regeneration in 
response to GTE- or GTEM-induced damage. 
Citric acid also demonstrated a positive fold-change in both treatment groups. 
Citrate, the species of citric acid present at a biological pH, is the first intermediate 
of the tricarboxylic acid (TCA) cycle; thus, an accumulation of citric acid may result 
from inadequate conversion of citrate to isocitrate in this pathway.121, 122, 124 Aside 
from a breakdown at this point potentially causing the build-up of citrate, it may also 
contribute to the energy demand driving the use of amino acids as an energy source. 
It is also worth noting that in healthy cells an excess of citrate can lead to the 
inhibition of phosphofructokinase, the enzyme which catalyses the rate-limiting 
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conversion of fructose-6-phosphate to fructose-1,6-bisphosphate in glycolysis.122 An 
accumulation of citric acid, therefore, may also be contributing to the shutdown of 
glycolysis, thus adding to the suspected cellular demand for non-carbohydrate 
energy sources that can bypass the glycolytic pathway.  
Another key observation was the positive fold-change in 9-octadecanoic acid, 
palmitic acid, 5,8,11-eicosatrienoic acid and an unidentified short-chain fatty acid in 
both treatment groups, as well as palmitelaidic acid in GTE-treated cells. Fatty acids 
are primary targets for free radical and singlet oxygen oxidations, which may result 
in the release of fatty acids into the cell and ultimately the disruption of cell 
membranes.130 It is therefore possible that the positive fold-change in fatty acids 
observed here may be due to membrane degradation as a result of oxidative stress.  
A positive fold-change was observed in the nucleobase uracil, which may be 
indicative of reduced RNA synthesis or increased pyrimidine degradation.122, 124 A 
reduction in RNA could lead to a decrease in protein synthesis, thus contributing to 
the positive fold-change observed in some amino acids. Alternatively, pyrimidine 
metabolism could indicate the degradation of DNA and RNA, which can also occur as 
a result of oxidative stress.122, 124 
Gallic acid demonstrated a large positive fold-change in both treatment types (>50), 
however given that this is not an endogenous compound, its contribution to the 
difference between treated cells and the controls is likely only due to cellular uptake 
of catechin gallates from the medium.121 The presence of gallic acid as its own entity 
could indicate its cleavage from catechin gallates within the cells although, given that 
HepG2 cells have little metabolic function, the extent to which this may have 
 78 
occurred is questionable.5 At the very least, the positive fold-change in gallic acid 
within both treatment groups likely indicates that catechin gallates were being taken 
up by the cells.  
3.3 Identification of GTE metabolites  
620 compounds were identified following GC-MS analysis of the metabolised GTE 
samples. After removing the alkanes and components present in the S9 controls and 
unmetabolised GTE, 521 compounds remained. 17 of these were present in ≥70% of 
the metabolised GTE samples; therefore, these were regarded as having the highest 
probability of being GTE metabolites (Table 3.2). 10 of the 17 suspected GTE 
metabolites were also detected in the metabolised catechin samples (Table S1-S4). 
One compound found in the unmetabolised GTE was also found in 100% of the 
metabolised GTE samples (RT: 31.1217, base peak: 281). This compound was 
putatively identified as gallic acid after exceeding all 3 match criteria outlined in 
section 2.4.4.3 when compared to the NIST library, thus it was retained in the list of 
suspected GTE metabolites due to it being a known component of catechins such as 
EGCG and ECG.51 The remaining 17 compounds suspected to be GTE metabolites 
were unable to be positively identified without further experimentation and analysis.  
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Table 3.2. Suspected metabolites of GTE following metabolism with S9 human liver fraction and 
frequency of detection using GC-MS analysis. GTE was metabolised at two concentrations: 1 mg/mL 
and 5 mg/mL (n = 10 for each concentration) *Components also detected in metabolised standards of 
CH, EC, EGC and/or EGCG. 
Compound RT (min) Base Peak 
Detected in 
samples (%) 
17 11.6083 116 85 
28* 16.2233 116 80 
116 17.2000 117 75 
126* 18.3283 99 95 
182* 21.4600 71 70 
184* 21.8900 75 90 
192* 22.8067 174 90 
217* 27.5300 299 95 
220 27.9300 174 90 
257* 31.1217 281 100 
258* 31.2017 72 75 
261 31.7450 147 75 
312* 33.2900 217 100 
318 34.5083 299 90 
337* 36.5400 147 90 
339 37.8117 299 95 
353 41.2500 361 95 
 
3.4 The effect of GTE on paracetamol-induced hepatotoxicity 
3.4.1 Cell density 
HepG2 cells from control samples reached approximately 80% confluence by the 
conclusion of the exposure period and the cells appeared to be healthy (Figure 3.9). 
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Confluence of cells exposed to APAP was estimated to be 70-75% and the cells again 
had a healthy appearance, although were aggregated in smaller clusters than those 
observed in the controls. Confluence of both the GTE- and APAP/GTE-treated 
samples was approximately 50-60% and it was difficult to distinguish any obvious 
difference between these treatment groups via microscopy. Cells in the GTE and 
APAP/GTE sample groups also formed smaller aggregates, similar to those observed 
in the APAP-treated cells. Cells exposed to GTE or the combined treatment had a 
darker appearance than the untreated controls and APAP-treated cells, and a colour 
change in the medium from pink to brown was observed.  
 
 
 
A) B) 
50 µM 50 µM 
50 µM 50 µM 
C) D) 
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Figure 3.9. Light microscope images at 100x magnification comparing untreated HepG2 cells (A) with 
those exposed to 1 mg/mL GTE (B), 15 mM APAP and 1 mg/mL GTE (C) or 15 mM APAP (D) for 24 h. 
 
In the untreated controls, the mean HepG2 cell concentration was 1.13 x 106 cells/mL 
(±	6.68 x 105) (Figure 3.10). The RSD determined from the concentration of 
untreated cells was 59.27%, which may be due to loss of cells during the removal of 
spent medium or the PBS wash step prior to trypsinising; therefore, untreated cell 
concentration was likely to be higher than described here. As outlined in section 
3.2.1, only two wells were used for performing cell counts; future studies should 
include at least three wells in order to provide a more accurate estimate of untreated 
cell concentration. Of the sample groups, the APAP-treated cells appeared to retain 
the greatest viability with a mean cell concentration of 6.80 x 105 cells/mL (±	1.13 x 
105).  
Little difference was demonstrated between the GTE-treated cells and those exposed 
to a combination of APAP and GTE, with mean cell concentrations found to be 3.45 x 
105 (±	7.07 x 103) and 3.55 x 105 cells/mL (±	7.78 x 104), respectively. This may be 
due to the GTE concentration of 1 mg/mL being too high, thus resulting in the effects 
of high-dose GTE masking the effects of APAP and GTE in combination. Based on the 
cell counts, it was not possible to determine whether the effects observed in the 
APAP/GTE treatment group were from the combined treatment or predominantly 
due to the high GTE dose. If this test were to be repeated, a lower GTE concentration 
should be used in order to better elucidate whether GTE aids or exacerbates APAP-
induced hepatotoxicity. All treatment groups demonstrated relatively low variation, 
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with the lowest RSD observed in GTE-treated cells (2.05%), followed by the APAP 
(16.64%) and APAP/GTE (21.91%) treatment groups 
As was observed in section 3.2.1, HepG2 cells were difficult to trypsinise post-
exposure to GTE and the combined APAP/GTE treatment, believed to be due to the 
GTE reacting with the well coating. As a result, approximately 80-90% of the cells 
resuspended successfully, therefore the actual cell concentrations for these 
treatment groups were slightly higher than described here. 
 
 
Figure 3.10. HepG2 cell concentration following exposure to 15 mM APAP, a combination of 15 mM 
APAP and 1 mg/mL GTE or 1 mg/mL GTE for 24 h compared to untreated controls (n = 2 for each 
sample group). Error bars indicate standard deviation.  
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3.4.2 Metabolomic analysis 
PCA was used to compare the three treatment groups with untreated controls 
(Figure 3.11). Controls and APAP-treated cells demonstrated a difference in 
metabolite profile compared to the GTE- and APAP/GTE-treated cells, with 22% of 
the observed variance explained by PC-1 and 16% by PC-2. No variance between the 
GTE and APAP/GTE treatment groups was able to be determined from the PCA plots, 
nor between the controls and APAP-treated samples. 
 
 
Figure 3.11. PCA scores plot using the first two principal components for comparison of HepG2 cell 
metabolite profile of untreated controls (blue) to cells exposed to 1 mg/mL GTE (green), 15 mM 
APAP/1 mg/mL GTE (purple) or 15 mM APAP (red) for 24 h, as measured by GC-MS analysis (n = 10 for 
each sample group). A difference was observed between the metabolite profiles of untreated controls 
and APAP-treated cells compared to GTE and the combined APAP/GTE treatment groups. No 
difference was observed in the metabolite profile of untreated cells compared to APAP-treated cells 
via PCA, nor between the GTE-treated cells compared to the combined treatment group. 
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The PLS-DA scores plot comparing the GTE-treatment group with untreated cells 
showed a difference in metabolite profile, 24% and 75% of which was explained by 
factor-1 (Figure 3.12a). Additionally, a difference was observed between untreated 
cells and the combined treatment group across factor-1, with 15% and 71% of the 
variance explained (Figure 3.12b). Most notably, a difference in metabolite profile 
was observed when the untreated cells were compared with the APAP treatment 
group, which had been difficult to distinguish in the PCA scores plot (Figure 3.12c). 
The variance observed here was explained 15% and 71% by factor-1. 
  
 85 
 
 
 
Figure 3.12. PLS-DA scores plots using the first two principal components (factors) for comparison of 
HepG2 cell metabolite profile in untreated controls (blue) to cells treated with: A) 1 mg/mL GTE 
(green), B) 15 mM APAP/1 mg/mL GTE (purple), and C) 15 mM APAP (red), as measured by GC-MS 
analysis (n = 10 for each sample group).  
A) 
B) 
C) 
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Two PLS-DA scores plots were produced comparing GTE-treated cells with the APAP 
and APAP/GTE treatment groups, with a difference in metabolite profile being 
observed in both. The difference observed between the GTE-treatment group and 
APAP-treated cells was 20% and 59% explained by factor-1 (Figure 3.13a). When 
comparing the GTE-treated cells with the combined treatment group, the difference 
observed was primarily across factor-1, with 26% and 46% of the variance explained 
(Figure 3.13b). 
Finally, an additional PLS-DA scores plot was constructed to compare APAP-treated 
cells with the combined treatment group. A difference in metabolite profile was 
again observed across factor-1, with 27% and 74% of the variance explained (Figure 
3.13c). 
 
  
 87 
 
 
Figure 3.13. PLS-DA scores plots using the first two principal components (factors) for comparison of 
HepG2 cell metabolite profiles following treatment with: A) 1 mg/mL GTE (green) vs. 15 mM APAP 
(red), B) 1 mg/mL GTE vs. 15 mM APAP/1 mg/mL GTE (purple), and C) 15 mM APAP vs. 15 mM APAP/1 
mg/mL GTE, as measured by GC-MS analysis (n = 10 for each sample group).  
A) 
B) 
C) 
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The PLS-DA X-loadings were used with a threshold of +/- 0.05 to identify the 34 
compounds contributing most to the variance between the sample groups (Figure 
S3, S4). When compared to the NIST library, 22 of these compounds met at least 2 of 
the 3 criteria defined in section 2.3.4.3 and thus were putatively deemed a match. 
After removing the compounds that were likely to be solvent-derived, 17 metabolites 
remained. 
Based on these 17 metabolites, a significant difference was observed between the 
profiles of untreated controls compared to GTE-treated cells (p=.001), and also 
between the controls and combined treatment group (p<.001) (Figure S5). 
Additionally, the metabolite profile of APAP-treated cells differed significantly from 
the GTE and combined treatment groups (p=.006 and <.001, respectively). No 
significant difference was observed between the controls and APAP-treated cells 
(p=.540), nor between the GTE and APAP/GTE treatment groups (p=.117). 
Of these 17 metabolites, 10 demonstrated a positive fold-change in comparison to 
the same compounds from control samples and 5 had a negative fold-change (Table 
3.3). The remaining 2 metabolites had mixed fold-changes across the treatment 
groups, however both of these were positive in the GTE-treated cells. Alanine 
demonstrated a negative fold-change in the APAP/GTE and APAP treatment groups, 
whilst myo-inositol had a negative fold-change in the APAP/GTE-treated cells and a 
positive fold-change in the APAP sample group. Of the amino acids, carbohydrates 
and fatty acids, the largest fold-changes were observed in b-alanine (GTE: 21.97, 
GTE/APAP: 21.23, APAP: 9.32), D-mannose (GTE: 2.64) and stearic acid (GTE: 5.51, 
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GTE/APAP: 6.98), respectively. All metabolites were found to differ significantly 
between sample groups, with the exception of alanine. 
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Table 3.3. Fold change observed in metabolites of HepG2 cells post-exposure to 1 mg/mL GTE, a 
combination of 15 mM APAP/1 mg/mL GTE or 15 mM APAP compared to untreated controls (n = 10 
for each sample group). Changes were primarily observed in amino acids and fatty acids. Green arrows 
indicate a positive-fold change compared to untreated controls and red arrows indicate a negative 
fold-change. *Metabolite differed significantly between sample groups, as determined by the Kruskal-
Wallis test (p<.05). †NIST match only met 2 of 3 match criteria outlined in section 2.4.4.3. 
Metabolite GTE APAP/GTE APAP 
Amino acids 
b-Alanine* ­ 21.97 ­ 21.23 ­ 9.32 
Alanine† ­ 1.14 ¯ 0.60 ¯ 0.86 
L-Threonine* ¯ 0.67 ¯ 0.19 - 
Serine* ¯ 0.61 ¯ 0.30 - 
L-Glutamic acid* ¯ 0.47 ¯ 0.08 - 
L-Lysine* - ¯ 0.41 - 
L-Isoleucine* ¯ 0.30 ¯ 0.12 - 
Carbohydrates 
D-Mannose*† ­ 2.64 - - 
Myo-inositol* ­ 1.06 ¯ 0.53 ­ 6.39 
Fatty acids 
Unidentified short-chain fatty acid*† ­ 9.60 ­ 10.48 ­ 1.74 
Stearic acid* ­ 5.51 ­ 6.98 - 
Oleic acid* ­ 5.10 ­ 7.13 - 
Palmitic acid* ­ 4.84 ­ 7.02 - 
Arachidonic acid* ­ 4.12 ­ 3.53 ­ 1.54 
Other 
Unidentified piperidine derivative* ­ 9.16 ­ 8.64 ­ 2.04 
Pipecolic acid* ­ 5.02 ­ 3.43 ­ 2.19 
Cholesterol* ­ 3.39 ­ 3.03 ­ 1.62 
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A large positive fold-change was observed in b-alanine across all three treatment 
groups, most notably in the GTE- and APAP/GTE-treated cells (>20-fold). b-alanine is 
a non-proteinogenic amino acid that is commonly metabolised to aspartic acid under 
normal conditions.122 In circumstances of increased energy demand, b-alanine can 
be converted into alanine and malonate semialdehyde: alanine can then be 
converted into pyruvate and fed into the TCA cycle; malonate semialdehyde can be 
converted to malonate, followed by malonyl CoA which then contributes to fatty acid 
synthesis.122, 124 b-alanine is also the rate-limiting precursor to the reactive oxygen 
species (ROS) scavenger carnosine, and it can be produced as a result of catabolism 
of pyrimidine nucleotides such as cytosine and uracil, which may occur as a result of 
DNA or RNA degradation.122, 124, 131 The positive fold-change observed here most 
likely reflects b-alanine production via pyrimidine catabolism in response to 
increased cellular demand for carnosine or as a result of DNA and RNA degradation, 
either of which could due to oxidative stress. Some b-alanine present in the cells may 
have undergone conversion to alanine and malonate semialdehyde, which may 
explain the positive fold-change in alanine observed in the GTE-treated cells.  
The amino acids L-threonine, serine, L-glutamic acid and L-isoleucine demonstrated 
a negative fold-change in GTE- and APAP/GTE-treated cells, and alanine 
demonstrated a negative fold-change in the APAP/GTE- and APAP-treated cells. This 
negative fold-change in amino acids could reflect a demand for alternative energy 
sources within the cells due to carbohydrate depletion or malfunction of the 
glycolytic pathway.122 Alanine, threonine, serine, glutamine and glutamic acid can all 
be converted into pyruvate and fed directly into the TCA cycle, allowing oxidative 
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phosphorylation to continue whilst bypassing glycolysis.122, 124 Additionally, 
isoleucine can be converted into acetyl CoA and fed directly into the TCA cycle.122, 124 
Thus, a reduction in these amino acids likely indicates a cellular demand for non-
carbohydrate energy sources in order to continue producing ATP whilst bypassing 
glycolysis. A positive fold-change was observed in the carbohydrates D-mannose and 
myo-inositol, contributing to the theory that treated cells may have lost the ability to 
use carbohydrates as an energy source. Aside from its use as an energy source, serine 
has been demonstrated to have an antioxidant role, thus it is possible that a negative 
fold-change in this amino acid could be due to its consumption as a free radical 
scavenger.127 
A negative fold-change in L-lysine was observed in the combined treatment group, 
which can be converted into acetyl CoA via the saccharopine pathway to be utilised 
in the TCA cycle.122, 124 Thus, as with the other amino acids found to have a negative 
fold-change in treated cells, it is possible that L-lysine was being used as an 
alternative energy source by the cells. All three treatment groups demonstrated a 
positive fold-change in pipecolic acid, a metabolite of lysine, supporting the theory 
that lysine was being degraded in the cells.122  
As outlined previously, myo-inositol is an integral component of inositol phosphates, 
secondary messengers involved in cellular signal transduction.128, 129 For example, 
InsP3 RI-dependent Ca2+ signalling has been found to play a role in the early stages 
of liver regeneration and the IRE1a regulation of hepatocyte proliferation via control 
of STAT3; therefore, it is possible that the positive fold-change observed in the GTE 
and APAP treatment groups reflects hepatocyte regeneration in response to GTE-
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induced hepatotoxicity.128, 129 The APAP/GTE treatment group demonstrated a 
negative fold-change in this compound, which may indicate consumption or 
depletion of inositol within the cells due to increased cytotoxicity. 
A positive fold-change was observed in stearic acid, oleic acid and palmitic acid in 
GTE- and APAP/GTE-treated cells, along with arachidonic acid and an unidentified 
short-chain fatty acid in all treatment groups. Cholesterol also demonstrated a 
positive fold-change in cells from all treatment groups. As outlined previously, lipid 
peroxidation resulting in disruption to cell membranes can occur during oxidative 
stress, thus the positive fold-changes observed in cholesterol and fatty acids may be 
a result of membrane degradation.130 Additionally, it is possible that the positive fold-
change in arachidonic acid may in part be due to an inflammatory response occurring 
within the cells.121  
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4. General discussion 
4.1. GTE-induced oxidative stress 
This study has demonstrated that GTE induces hepatotoxicity in HepG2 cells, 
inducing a wide range of biochemical changes which ultimately led to a decrease in 
cell concentration. Cells treated with GTE, GTE metabolites (GTEM) or a combination 
of APAP and GTE all demonstrated a loss in cell viability and changes in key cellular 
components, such as amino acids, fatty acids and carbohydrates. Given that the rise 
in herbal complementary and alternative medicine (HCAM) usage is showing no signs 
of slowing and that GTE is already very popular, the findings are particularly 
concerning and further contribute to the growing body of research suggesting that 
GTE is capable of causing herb-induced liver injury (HILI).1, 81, 95, 98 
The biochemical changes observed in this study were suggestive of lipid peroxidation 
and membrane damage, pyrimidine and protein degradation, increased cellular 
requirement for non-carbohydrate energy sources and disruption to glycolysis and 
potentially the TCA cycle, of which the latter may have occurred as a result of 
mitochondrial dysfunction.121, 122, 124 The changes observed in b-alanine may also 
reflect an increase in demand for the ROS scavenger carnosine.122, 124, 131 Additionally, 
the changes observed in myo-inositol suggests that an increase in inositol signalling 
was occurring, potentially in an attempt to carry out cellular repair and 
regeneration.128, 129 These biochemical pathways are commonly disrupted during 
oxidative stress, suggesting that the hepatocytes entered a pro-oxidant state.132, 133 
These findings are consistent with previous studies which have implicated oxidative 
stress in GTE-induced hepatotoxicity.40, 46, 95, 98, 99 
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Oxidative stress is characterised by an imbalance between free radicals and the 
antioxidants within the cell, and is commonly implicated in cytotoxicity and other 
disease processes.133, 134 Free radicals, such as ROS and reactive nitrogen species 
(RNS), are pro-oxidant molecules which are highly reactive due to the presence of at 
least one unpaired electron.134 In healthy cells, free radicals can be produced 
endogenously as by-products of processes such as aerobic respiration and at low 
concentrations have a number of beneficial physiological roles.134 Antioxidants 
protect the cells by preventing or repairing free radical damage.133, 134 During 
oxidative stress there is an overproduction of ROS and RNS or a deficiency in cellular 
antioxidants (or both), resulting in the inability to sufficiently neutralise free radicals 
and ultimately leading to the oxidation of important cellular molecules, such as lipids, 
proteins and nucleic acids, as observed in this study.132-134 Eventually, when cellular 
damage is beyond repair, oxidative stress leads to cell death; this may explain the 
significant decrease in cell concentration observed in the GTE, GTEM and APAP/GTE 
treatment groups. Future studies should measure oxidative stress in GTE-treated 
HepG2 cells in order to confirm that this process was occurring in the cells analysed 
in this study. 
To further investigate the role of oxidative stress in GTE-induced hepatotoxicity, 
direct or indirect approaches could be used to measure oxidative stress in vitro using 
markers such as ROS, lipid peroxidation, antioxidants, damage to DNA or RNA and 
oxidation or nitration of proteins.132 An example of a direct method commonly used 
to assess oxidative stress is the dichlorodihydrofluorescein diacetate (DCFDA) assay, 
which can be used to measure ROS, such as hydrogen peroxide, in cells.133, 135 DCFDA 
passively diffuses into cells and is subsequently hydrolysed to DCFH, which then 
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reacts with ROS to produce DCF as a fluorescent product.133, 135 This can be measured 
using flow cytometry or a microplate reader, with the intensity of fluorescence giving 
an indication of ROS levels, and therefore oxidative stress, within cells.133, 135 The 
major limitation of using ROS as a measure of oxidative stress is their transient 
nature, which may hinder the accuracy and precision of the results; this can be 
overcome by analysing oxidative damage, such as protein carbonyl content or lipid 
peroxidation, as an indirect measure of oxidative stress.132, 133  
A wide range of assays have been developed for the analysis of oxidative damage; 
for example, the thiobarbituric acid-reactive substances (TBARS) assay is a popular 
approach used to measure lipid peroxidation via the use of malondialdehyde (MDA) 
as a marker.132, 133, 136 In this assay, a conjugate is formed between thiobarbituric acid 
and MDA, which can be separated from other thiobarbituric acid conjugates using 
techniques such as high performance liquid chromatography (HPLC) and measured 
using fluorescence with the result giving an indication of lipid peroxidation within the 
cell.133, 136 The positive fold-change in fatty acids observed in this study possibly 
indicates lipid peroxidation, thus it may be useful to couple the TBARS assay with the 
DCFDA assay to confirm that GTE, GTEM and APAP/GTE treatments induce oxidative 
stress in HepG2 cells, an approach that has previously been used to assess this 
mechanism in this cell line.137, 138 
The observed changes in amino acids and carbohydrates in the GTEM, APAP/GTE and 
both GTE treatment groups may also be indicative of a disruption in cellular 
respiration. Disruption to glycolysis in response to GTE has previously been described 
in the literature, with a 2016 paper suggesting that epigallocatechin-3-gallate (EGCG) 
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directly inhibits phosphofructokinase.100, 101 The change in citric acid, or citrate at 
biological pH, observed in the GTEM and first GTE treatment groups suggests a 
possible disruption in the TCA cycle, leading to the accumulation of this 
intermediate.121 This suggests that the mitochondria may have been affected in GTE- 
and GTEM-treated cells. Mitochondrial dysfunction is commonly implicated in 
oxidative stress, and it has previously been found that the mitochondria may be a 
target for GTE constituents such as EGCG, with the resulting mitochondrial 
dysfunction and elevated antioxidant response being suggested as possible 
contributors to GTE-induced hepatotoxicity.40 
To confirm whether mitochondrial damage occurred, an assay such as the cellular 
ATP glucose-galactose shift assay may be used.139 Despite the reported reduced 
galactose metabolism in HepG2 cells, recent modifications to this assay have 
enhanced its sensitivity and specificity, thus enhancing the reliability of its results.139 
Whilst assays tend to be the most commonly adopted approach to measuring 
oxidative stress and mitochondrial dysfunction, metabolomic analysis has 
demonstrated promise in recent years with the potential to provide more sensitive 
and specific results via the use of HPLC, LC-MS/MS and GC-MS.136, 140 The cellular 
disturbances suspected to occur in HepG2 cells following exposure to various 
treatments of GTE are summarised in Figure 4.1. 
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Figure 4.1. Summary of cellular disturbances suspected to occur during GTE-induced hepatotoxicity 
based on the data from this study. Created with BioRender.com. 
 
4.2 GTE metabolites 
Given that, aside from gallic acid, the suspected GTE metabolites were unable to be 
putatively identified in the timeframe of this study, further analysis is required to 
determine the identity of these compounds. A 2019 paper described the use of LC-
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MS and nuclear magnetic resonance (NMR) spectroscopy to characterise variations 
in metabolite profile amongst cranberry supplements, thus a method similar to this 
would be ideal for the isolation and identification of the compounds in metabolised 
GTE samples.141, 142 The extent to which GTE was metabolised by S9 human liver 
fraction in the 1-h reaction period used in this study was not determined. Given that 
NMR signal intensity is directly proportional to the concentration of a given 
metabolite, it is inherently quantitative and so could also be used to determine the 
extent of GTE metabolism based on concentration of unmetabolised GTE 
constituents prior to commencing the reaction compared to the amount remaining 
at its conclusion.142 The information obtained from these metabolomic analyses 
could subsequently be used to determine the likelihood of a given compound being 
a GTE metabolite. 
The upper m/z limit of 1000 of the instrument used in this study may have inhibited 
the detection of larger GTE metabolites. For example, EGCG has a m/z of 648, making 
it possible that conjugated metabolites of EGCG may have been too large to be 
detected, thus reducing the number of compounds identified in the metabolised GTE 
samples.143 If the GTE metabolites produced in this study were to be characterised 
using LC-MS and NMR, the potential for large EGCG metabolites should be 
considered and modifications made in order to obtain the most comprehensive 
results. 
Another limitation to this section of the study was that it is possible that the 
metabolism carried out using S9 human liver fraction was not a complete 
representation of the metabolic processes normally carried out in hepatocytes in 
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vivo. Additionally, GTE constituents such as catechins have been shown to undergo 
extensive microbial metabolism in the intestine prior to absorption.61 It has also been 
found that catechins may be metabolised via methylation and sulfation in 
enterocytes prior to being absorbed into the portal vein.59, 62 These microbial and 
intestinal GTE metabolites are inevitably different to those produced by hepatocytes, 
thus it is possible that these conjugations may have a different level of toxicity to 
those observed in this study.59, 61, 62 It is also possible that hepatocytes are 
predominantly exposed to microbial and intestinal metabolites of GTE, and not the 
unmetabolised constituents analysed in this study, therefore further analysis is 
required to examine the toxicity of these metabolites in an effort to more 
comprehensively understand the compounds to which hepatocytes are exposed in 
vivo following ingestion of GTE.  
4.3 Future considerations 
This project had a number of limitations that may have impacted the in vivo relevance 
of the results obtained and which should be considered in future studies. The doses 
used in this study were chosen after having been demonstrated to induce 
cytotoxicity and were therefore not necessarily pharmacologically relevant.26, 117 
Whilst this allowed for the assessment of which biochemical pathways may have 
been affected in hepatocytes during GTE-induced hepatotoxicity, it may not be 
completely demonstrative of what occurs in individuals who develop liver damage in 
response to this HCAM. The length of treatment must also be taken into account 
when considering dosage; due to the limited timeframe, this study focused on acute, 
high doses in order to elicit a timely toxic response. Future studies should use 
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pharmacological doses and chronic exposure periods in order to better represent the 
conditions under which cases of GTE-induced liver damage have manifested.3, 4 
Bioavailability must also be taken into consideration, given the low oral 
bioavailability previously demonstrated in GTE components such as catechins, 
particularly when consumed in a fed state.33 Additionally, microbial metabolism of 
catechins results in a variety of conjugations and thus may impact their overall 
bioavailability.61 It is therefore likely that the GTE components and metabolites to 
which cells were exposed in this study were not a complete representation of what 
they may come into contact with in vivo. 
Whilst analysing hepatocyte metabolism in vitro is achievable, it is not possible to 
completely assess the pharmacokinetics of GTE using this model. Understanding the 
absorption, distribution and excretion of GTE constituents and metabolites in 
addition to their metabolism will be paramount to understanding and predicting the 
risk of toxicity induced by GTE, or other herbal medicines, in certain individuals. 
In addition to the pharmacology of GTE and its constituents, there are other factors 
which may contribute to the toxicity observed in certain individuals which could not 
be sufficiently examined in the timeframe of this study. For example, it has been 
demonstrated that the contamination and adulteration of herbal supplements is not 
only possible, but rife among these products.12, 144 Given that in many instances of 
liver damage the GTE product consumed has not been available for testing, it is 
difficult to rule out contamination or adulteration of these products leading to the 
liver damage reported. Given that this study did not characterise the composition of 
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the GTE product prior to cell exposures, contamination or adulteration cannot be 
ruled out as a possible contributor to the cytotoxicity observed. 
Genetic variation may also play a role in determining which individuals may be more 
predisposed to developing a liver injury when consuming GTE.34, 35, 86 For example, 
polymorphisms resulting in altered function or abundance of the enzymes 
responsible for the biotransformation of catechins may increase the likelihood of 
hepatotoxicity due to the potentially toxic accumulation of these compounds or the 
increased production of toxic metabolites.34 Additionally, changes in the proteins 
involved in Phase III detoxification could limit the clearance of catechins and 
metabolites from the liver, causing them to build up, potentially resulting in 
hepatotoxicity.24, 25 Future studies should examine whether any common genetic 
abnormalities are able to be identified amongst individuals who develop liver injury 
following supplementation with this HCAM. 
Co-medication with other herbal supplements or drugs could result in herb-herb or 
herb-drug interactions, which may contribute to certain individuals being more 
susceptible to developing GTE-induced liver damage.16, 17 In fact, a number of cases 
of liver damage in which GTE was identified as the most likely culprit have been in 
individuals using a supplement which contained GTE as one of many ingredients.4 It 
is possible that GTE could interact with other components present in these products 
to cause liver injury, and may not be as damaging when consumed in isolation at a 
safe dosage. Further research should be conducted in order to determine the 
composition of these products and whether the hepatotoxicity of these substances 
can really be narrowed down to a single component. 
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If this study were to be repeated, it may also be beneficial to use a different 
hepatocyte cell line, such as HepaRG. It is well established that HepG2 cell responses 
are not completely comparable to in vivo hepatocyte responses; for example, the 
diminished function of the CYP450 enzymes is a particular setback when assessing 
toxicity with this cell line.5 HepaRG cells are an immortalised cell line which have 
retained metabolic function, therefore these may be a better choice in future.5 
Additionally, using 3D cultures that include non-parenchymal liver cells may produce 
results more comparable to in vivo responses than the traditional 2D culture used in 
this study, given that they allow more complex cell-cell interactions.145 Of course, the 
gold standard would be to obtain primary human hepatocyte cultures, however this 
is unlikely to be an option until further evidence is gathered.5, 145 
A major challenge with GC-MS analysis is the formation of multiple derivatisation 
products. This makes it challenging to gain a complete understanding of a given 
metabolic profile due to the production of multiple results for the same compound. 
In this study, the method of overcoming this without further analysis was to select 
the result that appeared to contribute most to the variation between samples, and 
disregard the others. This is flawed and thus it would be more suitable to conduct 
further analysis using other forms of metabolomic analysis such as LC-MS and NMR 
spectroscopy, the complementarity of which was discussed in a 2018 systematic 
review.5  
4.4 Conclusion 
This study used in vitro techniques to analyse the hepatotoxicity of GTE and has 
demonstrated that this supplement is capable of causing HILI. Whilst this study only 
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analysed one GTE product available on the Australian market, it has highlighted the 
potential risk this supplement poses to consumer health. The results indicated that 
disruption to cellular respiration, proteins, nucleic acids and lipids were likely to have 
occurred in HepG2 cells following exposure to a range of GTE treatments, 
contributing to the growing body of evidence which suggests that GTE-induced 
hepatotoxicity occurs as a result of oxidative stress.40, 98, 99 Cells treated with 
metabolised GTE appeared to be less affected than those exposed to unmetabolised 
GTE, suggesting that the metabolism of GTE renders toxic parent compounds inert. 
In addition to determining the biochemical changes induced by GTE and the extent 
to which this is mediated by GTE metabolites, this study has also demonstrated that 
metabolomics is an effective and comprehensive tool for toxicological analysis. Using 
the method described in this study, it was possible to not only determine the end-
point toxicity but also provide insight into the mechanisms most likely driving the loss 
of cell viability observed in response to treatment with this herbal supplement. 
Metabolomics is therefore a valuable technique which should be incorporated into 
future studies investigating in vitro toxicology. 
This study focused on GTE, one of a number of HCAMs implicated in increasing cases 
of liver damage worldwide; particularly concerning given that consumers often 
purchase these herbal medicines in the belief that their natural origin is synonymous 
with them being safe. It is therefore imperative that appropriate steps are taken to 
ensure that the right measures are in place to prevent adverse reactions to HCAMs, 
such as the GTE-induced hepatotoxicity observed in this study, from continuing to 
contribute to morbidity and mortality in the Australian community.  
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6. Supplementary information 
 
 
 
Figure S1. X- and Y-loadings plot from which X-loadings were derived for analysis of metabolites 
contributing most to variance between untreated controls and GTE-treated cells (A), untreated 
controls and GTEM-treated cells (B), and GTE-treated and GTEM-treated cells (C), measured by GC-
MS.  
A) 
B) 
C) 
 126 
 
Figure S2. Kruskal-Wallis pairwise comparisons of sample groups: 1) untreated controls, 2) 1 mg/mL 
GTE treatment group, and 3) 1 mg/mL GTEM treatment group. All sample groups were prepared in 10 
replicates. A significance difference was observed between the metabolite profile of untreated cells 
compared to GTE-treated cells, and also between the controls and GTEM treatment group (p<.05). 
The metabolite profile of GTE-treated cells was not found to differ significantly from that of the GTEM 
treatment group. 
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Table S1. Unidentified metabolites of purified catechin hydrate (CH) following metabolism with S9 
human liver fraction and GC-MS analysis (n = 3). CH concentration prior to initiation of metabolism 
was 1 mg/mL. *Components also detected in metabolised green tea extract. 
Compound RT (min) Base Peak Detected in samples (%) 
3* 16.2233 116 100 
4 16.3883 174 66.66667 
6 16.5867 299 33.33333 
7 16.6250 205 33.33333 
9 17.4483 174 66.66667 
11 18.1433 184 33.33333 
12* 18.3283 99 100 
16 20.0817 74 66.66667 
17 20.0883 234 33.33333 
18 20.5533 217 100 
19* 21.4600 71 100 
20* 21.8900 75 33.33333 
22 22.3300 102 100 
24 22.6917 156 33.33333 
25* 22.8067 174 33.33333 
26 22.9350 84 100 
28 23.3650 220 33.33333 
29 24.7500 246 66.66667 
30 24.9850 127 100 
31 25.5600 86 100 
33 25.8867 260 66.66667 
34 27.0767 272 100 
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35 27.1850 217 100 
37* 27.5300 299 100 
38* 29.3017 174 100 
39 29.5017 103 33.33333 
41 29.7600 147 100 
43 29.9700 205 100 
45 30.3067 147 66.66667 
47 30.5050 147 100 
48* 31.1217 281 33.33333 
49* 31.2017 72 100 
50 31.4733 204 100 
53 32.3000 204 33.33333 
54 32.7633 117 100 
55 33.1600 217 100 
56* 33.2900 217 33.33333 
57 33.6017 315 100 
59 34.7783 213 33.33333 
60 34.7867 213 33.33333 
62 35.4400 75 100 
63 35.5317 75 100 
66 38.9583 217 33.33333 
67 38.9667 217 66.66667 
69 43.0033 204 100 
71 43.6683 204 100 
76 44.6267 169 33.33333 
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80 49.9000 361 100 
81 51.5033 204 66.66667 
 
Table S2. Unidentified metabolites of purified epicatechin (EC) following metabolism with S9 human 
liver fraction and GC-MS analysis (n = 3). EC concentration prior to initiation of metabolism was 1 
mg/mL. *Components also detected in metabolised green tea extract. 
Compound RT (min) Base Peak Detected in samples (%) 
3* 16.2233 116 33.33333 
4 16.3883 174 66.66667 
5 16.5783 299 66.66667 
8 16.6400 299 66.66667 
9 17.4483 174 66.66667 
10 17.7583 147 33.33333 
11 18.1433 184 33.33333 
12* 18.3283 99 66.66667 
13 20.0233 127 33.33333 
17 20.0883 234 66.66667 
18 20.5533 217 100 
19* 21.4600 71 33.33333 
20* 21.8900 75 33.33333 
22 22.3300 102 66.66667 
26 22.9350 84 33.33333 
27 22.9833 239 33.33333 
29 24.7500 246 66.66667 
30 24.9850 127 66.66667 
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31 25.5600 86 66.66667 
33 25.8867 260 66.66667 
34 27.0767 272 66.66667 
35 27.1850 217 100 
36 27.3767 174 33.33333 
37* 27.5300 299 66.66667 
38* 29.3017 174 33.33333 
39 29.5017 103 66.66667 
41 29.7600 147 66.66667 
43 29.9700 205 100 
45 30.3067 147 100 
47 30.5050 147 100 
48* 31.1217 281 100 
49* 31.2017 72 66.66667 
50 31.4733 204 100 
52 32.1933 297 33.33333 
54 32.7633 117 100 
55 33.1600 217 66.66667 
56* 33.2900 217 33.33333 
57 33.6017 315 100 
58 33.6750 315 33.33333 
60 34.7867 213 33.33333 
62 35.4400 75 100 
63 35.5317 75 100 
64 35.9400 117 33.33333 
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65* 36.5400 147 33.33333 
66 38.9583 217 33.33333 
67 38.9667 217 33.33333 
69 43.0033 204 100 
70 43.0817 280 33.33333 
71 43.6683 204 100 
75 44.5950 169 33.33333 
80 49.9000 361 100 
81 51.5033 204 66.66667 
 
Table S3. Unidentified metabolites of purified epigallocatechin (EGC) following metabolism with S9 
human liver fraction and GC-MS analysis (n = 3). EGC concentration prior to initiation of metabolism 
was 1 mg/mL. *Components also detected in metabolised green tea extract. 
Compound RT (min) Base Peak Detected in samples (%) 
3* 16.2233 116 66.66667 
4 16.3883 174 66.66667 
6 16.5867 299 100 
9 17.4483 174 100 
12* 18.3283 99 66.66667 
14 20.0383 72 33.33333 
17 20.0883 234 66.66667 
18 20.5533 217 100 
19* 21.4600 71 100 
22 22.3300 102 100 
24 22.6917 156 33.33333 
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25* 22.8067 174 66.66667 
26 22.9350 84 66.66667 
28 23.3650 220 33.33333 
29 24.7500 246 100 
30 24.9850 127 100 
31 25.5600 86 100 
33 25.8867 260 100 
34 27.0767 272 100 
35 27.1850 217 100 
37* 27.5300 299 100 
38* 29.3017 174 33.33333 
39 29.5017 103 66.66667 
40 29.6867 103 33.33333 
41 29.7600 147 66.66667 
43 29.9700 205 100 
45 30.3067 147 66.66667 
47 30.5050 147 100 
48* 31.1217 281 66.66667 
49* 31.2017 72 100 
50 31.4733 204 100 
51 32.1900 297 33.33333 
54 32.7633 117 100 
55 33.1600 217 66.66667 
57 33.6017 315 100 
59 34.7783 213 33.33333 
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62 35.4400 75 66.66667 
63 35.5317 75 100 
66 38.9583 217 33.33333 
67 38.9667 217 33.33333 
68 40.6250 217 33.33333 
69 43.0033 204 100 
71 43.6683 204 100 
80 49.9000 361 100 
81 51.5033 204 100 
 
Table S4. Unidentified metabolites of purified epigallocatechin-3-gallate (EGCG) following metabolism 
with S9 human liver fraction and GC-MS analysis (n = 3). EGCG concentration prior to initiation of 
metabolism was 1 mg/mL. *Components also detected in metabolised green tea extract. 
Compound RT (min) Base Peak Detected in samples (%) 
3* 16.2233 116 66.66667 
4 16.3883 174 66.66667 
6 16.5867 299 33.33333 
8 16.6400 299 33.33333 
9 17.4483 174 66.66667 
12* 18.3283 99 33.33333 
15 20.0533 234 33.33333 
16 20.0817 74 33.33333 
17 20.0883 234 33.33333 
18 20.5533 217 100 
19* 21.4600 71 66.66667 
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20* 21.8900 75 33.33333 
22 22.3300 102 66.66667 
23 22.3533 84 33.33333 
24 22.6917 156 33.33333 
26 22.9350 84 33.33333 
27 22.9833 239 33.33333 
29 24.7500 246 66.66667 
30 24.9850 127 66.66667 
31 25.5600 86 66.66667 
32 25.8317 103 33.33333 
34 27.0767 272 66.66667 
35 27.1850 217 66.66667 
37* 27.5300 299 66.66667 
38* 29.3017 174 33.33333 
39 29.5017 103 66.66667 
41 29.7600 147 66.66667 
42 29.9050 204 33.33333 
43 29.9700 205 66.66667 
45 30.3067 147 66.66667 
46 30.3783 205 33.33333 
47 30.5050 147 66.66667 
48* 31.1217 281 66.66667 
49* 31.2017 72 66.66667 
50 31.4733 204 66.66667 
53 32.3000 204 33.33333 
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54 32.7633 117 66.66667 
55 33.1600 217 33.33333 
57 33.6017 315 66.66667 
59 34.7783 213 33.33333 
62 35.4400 75 33.33333 
63 35.5317 75 66.66667 
66 38.9583 217 66.66667 
69 43.0033 204 66.66667 
71 43.6683 204 66.66667 
80 49.9000 361 66.66667 
81 51.5033 204 33.33333 
83 54.6150 560 66.66667 
84 54.6417 560 33.33333 
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Figure S3. X- and Y-loadings plot from which X-loadings were derived for analysis of metabolites 
contributing most to variance between untreated HepG2 cells and A) GTE-treated cells, B) APAP/GTE-
treated cells, and C) APAP -treated cells, measured by GC-MS. 
  
A) 
B) 
C) 
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Figure S4. X- and Y-loadings plot from which X-loadings were derived for analysis of metabolites 
contributing most to variance between HepG2 cells treated with GTE vs APAP (A), GTE vs APAP/GTE 
(B), and APAP vs APAP/GTE (C), measured by GC-MS. 
  
A) 
B) 
C) 
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Figure S5. Kruskal-Wallis pairwise comparisons of sample groups: 1) untreated controls, 2) 1 mg/mL 
GTE-treated cells, 3) 15 mM APAP-treated cells, and 4) 15 mM APAP/1 mg/mL GTE combined 
treatment group. All sample groups were prepared in 10 replicates. A significant difference was 
observed between the metabolite profiles of untreated controls compared to both the GTE-treated 
cells and the combined treatment group (p<.05). The metabolite profile of APAP-treated cells differed 
significantly from the GTE and combined treatment groups. No significant difference was observed 
between the controls and APAP-treated cells, nor between the GTE and APAP/GTE treatment groups. 
